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Abstract  
Individuals high in anxiety sensitivity (AS), a cognitive risk factor denoting a fear 
of anxiety-related sensations (Reiss & McNally, 1985), may be at increased risk of 
misinterpreting nicotine withdrawal-relevant interoceptive cues as harmful, thus 
amplifying their risk for panic problems. This study tested the moderating role of AS on 
the association between nicotine withdrawal and panic-relevant responding to a carbon 
dioxide-enriched air laboratory challenge.  Specifically, it was hypothesized that AS 
moderates the relation between nicotine withdrawal (group status) and responding to a 
carbon dioxide-enriched air procedure (controlling for anticipatory anxiety, gender, 
negative affectivity, number of axis I diagnoses, and average daily smoking rate), as 
indexed by: (1) level of anxiety focused on bodily sensations and intensity of panic attack 
symptoms; (2) skin conductance reactivity; and (3) level of behavioral avoidance of a 
future challenge. To test this hypothesis, 90 daily smokers (35 women; Mage = 28.87, SD 
= 12.12, Range = 18-60 years) were enrolled and enlisted to attend two study sessions. 
At the conclusion of the first session, participants were randomly assigned to one of two 
groups (12-hour nicotine deprivation or smoking ‗as usual‘). At the second scheduled 
session, participants in both groups underwent a 10% carbon dioxide-enriched air 
laboratory challenge to assess panic-relevant responding. Contrary to hypothesis, the 
AS by nicotine withdrawal (group status) interactive effect was not significantly predictive 
of post-challenge anxiety, panic attack symptoms, skin conductance reactivity, or 
behavioral avoidance. However, post hoc tests indicated that the AS by nicotine 
withdrawal (group status) interaction was significantly predictive of peri-challenge anxiety 
ratings. Furthermore, post hoc tests demonstrated that between-group (significant) 
differences in withdrawal symptoms diminished after the first assessment of the 
challenge session. Results are discussed in the context of the theoretical and clinical 
implications of the current work, limitations of the current study, and future directions for 
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 The overarching aim of the present investigation was to delineate empirical 
linkages and interactive effects between a cognitive risk factor for panic disorder (PD), 
anxiety sensitivity (AS; fear of anxiety), and acute (12-hour) nicotine withdrawal in order 
to better understand the etiology of panic vulnerability processes. To provide a 
framework for the current study and contextualize the relevance of AS and nicotine 
withdrawal in terms of panic vulnerability, the present document reviews the theoretical 
and empirical literature related to the following domains: (1) clinical significance of panic-
related psychopathology; (2) clinical significance of smoking; (3) co-occurrence of 
smoking and panic psychopathology; (4) associations between smoking and onset and 
concurrence of panic psychopathology; (5) AS and smoking; (6) nicotine withdrawal and 
panic vulnerability; and (7) nicotine withdrawal and AS. 
Background and Significance 
Panic-Spectrum Psychopathology: Clinical Significance 
Panic attacks.  Panic attacks are a subjective sense of extreme fear or 
impending doom accompanied by an autonomic nervous system surge and a strong 
flight-or-fight action tendency (Barlow, Brown, & Craske, 1994). Recent estimates of 
unexpected (―out of the blue‖) panic attacks in representative samples suggest that 
approximately 20% of individuals experience such attacks at one point in their lives and 
11.2% have experienced such attacks in the past 12 months (Kessler, Chiu, Jin, Ruscio, 
Shear, & Walters, 2006), indicating that it is a relatively common psychological 
experience. These findings are generally consistent with earlier investigations using non-
representative samples (e.g., Craske, Brown, Meadows, & Barlow, 1995). Many people 
experience panic attacks without necessarily developing PD (i.e., nonclinical panic 
attacks; Norton, Cox, & Malan, 1992). Typically, individuals who experience nonclinical 
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panic attacks do not experience these attacks as ―spontaneous‖ or ―uncued‖ as is 
generally the case in PD, but rather in certain contexts such as stressful or threatening 
social situations (Norton, 1989). Such panic attacks can occur among those with and 
without other types of psychopathology (i.e., Bryant & Panasetis, 2005). Even when not 
accompanied by PD, panic attacks can be associated with increased rates of disability 
and role impairment (Kessler et al., 2006). Panic attack onset tends to first occur 
between the ages of 12-13 years (Hayward et al., 1992; Macaulay & Kleinknecht, 1989; 
Warren & Zgourides, 1988). Important interpretative caveats to these investigations, 
however, are that they have focused almost exclusively on youth. These rates of onset 
should thus be considered useful guides for estimating onset but as of yet cannot be 
viewed as definitive. 
Panic disorder (PD).  PD involves recurrent, unexpected panic attacks and 
anxious apprehension about the possibility of experiencing future panic episodes 
(American Psychiatric Association [APA], 2000). Lifetime estimates of PD with 
agoraphobia and PD without agoraphobia are 1.1% and 3.7%, respectively (Kessler et 
al., 2006). Twelve-month estimates for PD (with or without agoraphobia) are 
approximately 2.8% (Kessler et al., 2006). Thus, PD is a relatively common psychiatric 
disorder when considered from both lifetime and 12-month prevalence rates. This clinical 
condition is generally regarded as a disorder of adulthood with a median age of onset of 
24 years (Burke, Burke, Regier, & Rae, 1990), although some emerging research has 
noted that another possible ―peak onset period‖ may be between ages 45-54 years 
(Burke et al., 1990). PD with and without agoraphobia is associated with a chronic, 
fluctuating course, high rates of healthcare utilization, and high rates of both psychiatric 
comorbidity and substance use disorders (Brown & Barlow, 1992; Zvolensky, Bernstein, 
Marshall, & Feldner, 2006). 
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Agoraphobia.  Individuals with PD often show some signs of avoidance of 
potentially threatening situations (Feldner, Zvolensky, & Leen-Feldner, 2004), although 
not all persons with this disorder will meet diagnostic criteria for agoraphobia. 
Agoraphobia often reflects a pattern of behavior characterized by consistent avoidance 
of threatening situations where a panic attack, or high levels of anxiety, is perceived to 
be likely to occur (e.g., limited options to escape); or the experience of marked emotional 
distress when in such situations. Avoidance behavior can be multifaceted, ranging from 
certain physical environments to more specific stimuli (e.g., certain substances like 
caffeine; Rapee, Craske, & Barlow, 1995). Although agoraphobia does not necessarily 
require the presence of panic attacks or PD (Fava, Grandi, & Canestrari, 1988), many 
researchers conceptualize agoraphobia as a complication of (severe) PD (Barlow, 
2002). Agoraphobia with or without PD often is related to higher rates of clinically 
significant life impairment and severity of illness (Kessler et al., 2006). The onset of 
agoraphobia with or without PD is not as firmly established as that of panic attacks and 
PD, although some research suggests it may occur later in life (Lindesay, 1991).  
Smoking: Clinical Significance 
Cigarette smoking is the most popular form of tobacco use (Windle & Windle, 
1999), and it is a leading preventable cause of death and disability in the United States 
([U.S.], Centers for Disease Control and Prevention [CDC], 1994). Smoking is a major 
causal or complicating factor in various types of medical illness, including heart disease, 
a variety of pulmonary diseases (e.g., chronic obstructive pulmonary disease), and 
several types of cancer (U.S. Department of Health and Human Services, 2000). 
Moreover, smoking is responsible for approximately 31% of all cancer-related deaths in 
the U.S. (American Cancer Society, 2006). Although smoking increases one‘s risk for 
developing a variety of lethal medical diseases, quitting smoking decreases the risk of 
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developing such problems and may increase the survival time among those persons 
who have already developed medical problems (Samet, 1992). 
Despite a reduction in smoking prevalence over the past 25 years, approximately 
45 million to 48 million (approximately 22% to 25%) adults in the U.S. currently smoke 
(CDC, 1996). In addition, research has shown that approximately 64% of adolescents 
report having smoked cigarettes and 14% report smoking in the past month (i.e., 20 out 
of the past 30 days; CDC, 2002), evidencing the maintained prevalence of smoking 
among youth.  Though approximately 70% of current smokers report motivation to quit 
smoking (CDC, 1999), 90% to 95% of smokers who quit smoking on their own (Garvey, 
1988) and 60% to 80% of those who attend smoking cessation treatment programs 
relapse to smoking (Brown & Emmons, 1991).  
Co-occurrence of Smoking and Panic Psychopathology  
Both community-based and representative studies have examined the extent of 
the co-occurrence between smoking and panic psychopathology. Investigations have 
consistently found a positive association between smoking and a history of panic attacks 
and PD (Amering et al., 1999; Degenhardt, Hall, & Lynskey, 2001; Glassman et al., 
1990; Hughes, Hatsukami, Mitchell, & Dahlgren, 1986; Pohl, Yeragani, Balon, Lycaki, & 
McBride, 1992; Tilley, 1987).  
Studies of treatment-seeking adults.  Among treatment-seeking adults, several 
studies have reported that, among patients with panic psychopathology (either PD or 
agoraphobia or both), rates of current daily smoking ranged from 19% (Baker-
Morissette, Gulliver, Wiegel, & Barlow, 2004) to 57% (Himle, Thyer, & Fischer, 1988), 
with the majority of investigations finding rates between 30% to 50% (Amering et al., 
1999; Lopes et al., 2002; McCabe et al., 2004; Pohl et al., 1992). These rates of 
smoking are generally higher than among comparison groups of individuals without 
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psychiatric problems and typically higher — or as high as — rates among individuals 
with other anxiety or mood disorders (McCabe et al., 2004). These data collectively 
suggest that smoking is relatively common among treatment-seeking individuals with 
panic psychopathology. 
Community-based studies.  Two studies examining prevalence rates of 
smoking and panic psychopathology using community-based samples have been 
conducted to date (Hayward, Killen, & Taylor, 1989; Valentiner, Mounts, & Deacon, 
2004). Hayward et al. (1989) examined 95 ninth grade public school students, while 
Valentiner et al. (2004) examined 337 college students.  Both investigations found that 
individuals with panic attacks, but not necessarily those with PD or agoraphobia, 
reported higher rates of regular smoking (Hayward et al., 1989; Valentiner et al., 2004). 
For example, Hayward et al. (1989) reported that 77% of individuals with a lifetime 
history of panic attacks had engaged in ―experimental‖ or ―regular‖ smoking compared to 
only 48% of adolescents without a lifetime history of panic attacks. These findings 
generally parallel those noted in studies of treatment-seeking individuals with panic 
psychopathology.   
 Studies using representative samples. Several studies have utilized 
representative sampling to examine smoking rates among those with panic 
psychopathology (Covey, Hughes, Glassman, Blazer, & George, 1994; Farrell et al., 
2001; Lasser et al., 2000), and conversely, to examine rates of panic psychopathology 
among smokers (Black, Zimmerman, & Coryell, 1999; Breslau, Kilbey, & Andreski, 1991; 
Goodwin, Zvolensky, & Keyes, 2007; Nelson & Wittchen, 1998). In the most 
comprehensive representative study, based on data from the National Comorbidity 
Survey (NCS), a nationally-based study that used structured clinical interviews to 
document prevalence rates of psychopathology (Kessler et al., 1994), Lasser et al. 
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(2000) examined smoking rates corresponding to psychiatric diagnoses. Participants 
were 4,411 individuals, aged 15 to 54 years, residing in the U.S.  Lasser et al. (2000) 
reported that rates of smoking were highest among individuals with panic-related 
problems (i.e., history of panic attacks, PD, and agoraphobia) and other anxiety 
disorders where panic attacks are common (i.e., posttraumatic stress disorder; Lasser et 
al., 2000). Among individuals diagnosed with panic attacks, PD, and agoraphobia in their 
lifetime, 38%, 35%, and 38% were current smokers, respectively. These rates were 
significantly greater than rates of current smoking among individuals without mental 
illness (22%). By comparison, 36% of individuals with a lifetime history of major 
depression and 49% of individuals with a lifetime diagnosis of drug abuse or 
dependence were current smokers. Rates of lifetime smoking among persons with a 
lifetime history of panic psychopathology (i.e., panic attacks, PD, or agoraphobia) ranged 
from 58% to 61%. When diagnostic status in the past month was used as the grouping 
variable, current rates of smoking were 46% among persons with panic attacks, 42% 
among persons with PD, and 48.1% among persons with agoraphobia. It is noteworthy 
that as number of mental diagnoses increased (ranging from 0 to 4 or more), the 
percentage of heavy (i.e., peak consumption exceeding 24 cigarettes a day) compared 
to relatively lighter (i.e., peak consumption less than 24 cigarettes per day) smokers 
increased. Overall, these data suggest that smoking occurs at relatively higher rates 
among those with panic psychopathology compared to those with no mental illness; and 
that heavier smoking may be associated with more severe psychopathology (i.e., higher 
number of comorbid diagnoses).  
Other investigations have sought to evaluate rates of panic psychopathology 
among smokers (Black et al., 1999; Breslau et al., 1991; Goodwin et al., 2007; Nelson & 
Wittchen, 1998). All of these investigations except that by Black and colleagues (1999), 
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which reported community-based recruitment, involved some sort of representative 
sampling strategy. In contrast to the studies reviewed earlier, these investigations 
attempted to understand panic within the context of tobacco dependence and severity. 
Here, across studies, results indicated that among those persons meeting criteria for 
more addictive use of cigarettes (e.g., nicotine dependence), there is a greater 
prevalence of panic psychopathology (Breslau et al., 1991). For example, Breslau and 
colleagues (1991) found that 6.6% of persons meeting criteria for moderate nicotine 
dependence, 4.8% of those with mild nicotine dependence, and 2.4% of those with no 
nicotine dependence had a lifetime diagnosis of PD. Nelson and Wittchen (1998) 
similarly found that, among participants endorsing a lifetime history of smoking (yes/no), 
7.6% met lifetime diagnostic criteria for panic attacks, 2% for PD, and 4.4% for 
agoraphobia. These rates of panic psychopathology were significantly greater than those 
reported among nonsmokers of whom 2.4% had a panic attack history, 0.7% had PD, 
and 1.6% had agoraphobia. Smokers with a lifetime nicotine dependence diagnosis, 
compared to smokers without such a diagnosis, evidenced greater rates of panic attacks 
(11.3% versus 4.0%), PD (2.2% versus 1.8%), and agoraphobia (6.4% versus 2.5%). It 
should be noted that a similar, albeit not uniform, pattern of findings was apparent for 
individuals with other psychiatric disorders (e.g., alcohol dependence, drug 
dependence). Overall, the extant literature suggests that heavier rates of smoking 
(greater degrees of dependence) are associated with a greater rate of comorbidity with 
panic psychopathology.  
Smoking: Association with Onset of and Concurrence with Panic Problems 
Developmental course. The onset of daily smoking typically occurs between the 
ages of 15 and 20 and rarely after age 25 (Breslau, Johnson, Hiripi, & Kessler, 2001). 
For example, the CDC reports that in the U.S., approximately 3,900 adolescents 
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between the ages of 12 and 17 years initiate cigarette smoking each day (CDC, 2004), 
and an additional 1,500 become daily cigarette smokers each day (Substance Abuse 
and Mental Health Services Administration, 2006). 
While the median age of onset for PD is approximately 24 years of age (Burke et 
al., 1990), the typical age of onset for panic attacks is between the ages of 12 to 13 
years (Goodwin & Gotlib, 2004; Hayward et al., 1992; Warren & Zgourides, 1988). For 
example, Goodwin and Gotlib (2004) reported that the mean age of panic attack onset 
was 13.4 years (n = 1,285; age range: 9 – 17 years). Other studies based on community 
or school samples have found similar results, with the modal age of onset of panic 
attacks being age 12 (Hayward et al., 1992; Warren & Zgourides, 1988); clinical samples 
report a slightly younger age of panic attack onset (Alessi & Magen, 1988; Black & 
Robbins, 1990). These data suggest that smoking initiation may typically precede the 
onset of PD.  However, one important interpretative caveat to these investigations is that 
they focus exclusively on youth and expressly do not sample from a larger age range. 
Thus, it is possible that the ―average‖ age of onset of panic attacks may be different if 
the sampling strategy incorporated adults.  
In fact, reports of smokers with ―active panic problems‖ are not entirely consistent 
with this perspective. For example, Amering and colleagues (1999) examined 102 
consecutive PD patients with or without agoraphobia attending an academic treatment 
clinic in Austria. Participants were diagnosed using a structured clinical interview and 
queried about their smoking status. Individuals presenting with ―severe somatic illness‖ 
and comorbid depression and other psychiatric illnesses were excluded from the study. 
Amering and colleagues (1999) reported that the onset of smoking preceded the onset 
of PD (cf. panic attacks) by 12.3 years (SD = 9.4) in a community sample of individuals 
with the condition (n = 102). Furthermore, Bernstein, Zvolensky, Schmidt, and Sachs-
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Ericsson (2007) directly evaluated onset patterns among 4,409 adults (Mage = 33.1, SD = 
10.7, women = 2,221) from the NCS (Kessler et al., 1997). Results indicated that, among 
individuals with a lifetime history of comorbid daily smoking and panic attacks (n = 167), 
the onset of daily smoking (M = 16.0 years, SD = 3.0) preceded the onset of panic 
attacks (M = 27.8 years, SD = 7.6) in the majority, but not among all, of the individuals 
reporting co-occurring smoking and panic psychopathology (63.7%, n = 106). A relatively 
large minority of comorbid cases (33%; n = 55) reported that panic attacks (M = 11.4 
years, SD = 5.2) preceded the onset of daily smoking (M = 18.2 years, SD = 4.7). The 
concurrent (same year) onset of these two problems appeared rarely (3.3%, n = 6). Also, 
as the pattern of ages of onset above illustrates, daily smoking demonstrated a relatively 
consistent mean age of onset (middle to late adolescence) across comorbid sub-
samples and the uni-morbid sub-sample of smokers (age 18.5 years). In contrast, the 
mean ages of onset of panic attacks differed markedly between the comorbid sub-
samples and the uni-morbid sub-sample of nonsmokers with panic attacks (age 20.3 
years).  
  Prospective studies.  Prospective studies offer unique insight into the nature of 
the observed relations over time, and by extension, the order or temporal sequence of 
the associations. Researchers have evaluated the association between smoking and risk 
of panic psychopathology in a number of studies. Breslau and Klein (1999) tested the 
association between daily smoking and risk for panic attacks and PD. Participants were 
drawn from two separate epidemiologically-defined data sets. Across both data sets, 
results indicated that there was a significant lifetime and prospective association 
between daily smoking and onset of panic attacks and PD; daily smokers were almost 4 
times more likely to experience panic attacks and 13 times more likely to develop PD 
after controlling for major depression and gender. Additionally, among individuals who 
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continued to smoke, compared to those who had quit, there was a significantly increased 
risk for experiencing a panic attack and PD. Furthermore, Johnson et al. (2000) 
investigated the longitudinal association between cigarette smoking and anxiety 
disorders among 688 youth. Heavy smoking (≥ 20 cigarettes per day) during 
adolescence was associated with a higher risk of developing PD and agoraphobia during 
early adulthood, even after controlling for a variety of theoretically-relevant factors (e.g., 
alcohol and other drug use, parental history of psychopathology, temperament, 
socioeconomic status). Additionally, smoking did not increase the risk of developing 
other anxiety disorders such as obsessive-compulsive disorder, thus indexing specificity 
with respect to panic-related problems. There also was no evidence that PD or another 
anxiety disorder during adolescence was associated with an increased risk of chronic 
cigarette use in young adulthood.  
In another prospective study recently completed in Germany, 2,500 participants 
(ages 14-24 years at baseline) were evaluated over 4 years (Isensee, Wittchen, Stein, 
Höfler, & Lieb, 2003). Compared with all other levels of smoking, dependent regular 
smokers at baseline were significantly more likely to develop panic attacks and PD, and 
a similar pattern was observed for agoraphobia. Similarly, Breslau, Novak, and Kessler 
(2004) evaluated daily smoking and the subsequent onset of psychiatric disorders. 
Results indicated that the onsets of PD (odds ratio = 2.6) and agoraphobia (odds ratio = 
4.4) were associated with pre-existing daily smoking after controlling for age, gender, 
ethnicity, and educational level. Additionally, after controlling for pre-existing psychiatric 
disorders and sociodemographic characteristics, current nicotine dependent smokers 
were significantly more likely to meet diagnostic criteria for PD compared to current non-
dependent smokers and former smokers. Importantly, the likelihood of PD and 
agoraphobia was significantly reduced with increased time since quitting; and these 
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effects were specific to these conditions and not other psychiatric disorders. More 
recently, Goodwin, Lewinsohn, and Seeley (2005) replicated the results of Breslau and 
Klein (1999), Johnson et al. (2000), and Isensee et al. (2003) by finding that daily 
smoking during adolescence was associated with an increased risk for panic attacks and 
PD in young adulthood. Moreover, the observed effects were no longer evident after 
controlling for parental smoking and anxiety disorder status, suggesting that these family 
history characteristics may be formative in the linkages between smoking and panic 
psychopathology. 
While data focused expressly on developmental course and smoking-panic 
psychopathology is limited, extant studies suggest that the majority of cases may involve 
smoking preceding panic attacks and PD.  Taken together, it seems that smoking is 
associated with increased risk for developing panic psychopathology (Breslau & Klein, 
1999; Isensee et al., 2003; see Zvolensky, Feldner, Leen-Feldner, & McLeish, 2005, for 
a review).  These same studies (e.g., Lasser et al., 2000) suggest that the observed 
association between smoking and panic psychopathology is not due to 
sociodemographic characteristics (e.g., gender), other psychiatric conditions (e.g., major 
depressive disorder, alcohol use), or symptom overlap in diagnostic criteria for anxiety 
disorders and nicotine dependence (Zvolensky, Schmidt, & Stewart, 2003).  
Smoking and maintenance of panic psychopathology.  It is important to 
briefly note that smoking might still theoretically contribute to maintenance processes 
relevant to comorbidity among individuals who meet criteria for two or more disorders 
(Zvolensky, Schmidt, & Stewart, 2003); though there is little empirical work on this topic. 
Furthermore, there is some limited work suggesting that smoking among those with 
panic attacks or PD is associated with more severe panic problems (Zvolensky, Forsyth, 
Fuse, Feldner, & Leen-Feldner, 2002; Zvolensky, Schmidt, & McCreary, 2003). Although 
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these studies are not solely focused on the etiology of PD per se, they provide further 
evidence of a smoking-panic association. For example, Zvolensky, Schmidt, and 
McCreary (2003) found that treatment-seeking smokers with PD compared to 
nonsmokers with PD reported more severe and intense anxiety symptoms, greater 
interview-based overall severity ratings of panic symptoms, and more social impairment. 
In these investigations, effects did not vary by gender, age, or other forms of substance 
use. Moreover, there is emerging evidence that these types of effects are relatively 
specific to PD and psychopathology that frequently co-occurs with panic (e.g., 
posttraumatic stress disorder; Feldner, Babson, & Zvolensky, 2007). For example, 
Morissette, Brown, Kamholz, and Gulliver (2006) found that smokers with anxiety 
disorders, as compared to their non-smoking counterparts, reported higher levels of AS 
(i.e., fear of anxiety and bodily-related sensations; McNally, 2002; reviewed below), 
anxiety symptoms, and agoraphobic avoidance. However, this association was specific 
to PD and not evident for any of the other studied anxiety disorders, which did not 
include posttraumatic stress disorder (Morissette et al., 2006).  
Laboratory studies have yielded similar results. As one illustrative example, 
Zvolensky, Leen-Feldner et al. (2004) employed a voluntary hyperventilation paradigm to 
examine associations between smoking and fearful responding to bodily sensations 
among 61 adults from the community (40 women; Mage was 24.8 [SD = 7.8]). One-third 
of the sample met diagnostic criteria for current PD (primary diagnosis) and consisted of 
regular smokers; one-third met only the diagnostic criteria for current PD (primary 
diagnosis) but was comprised of non-smokers; and the final third consisted of regular 
smokers who did not meet criteria for PD or any other type of psychopathology. Results 
indicated that smokers with PD reported greater levels of anxiety, as compared to 
smokers without PD, at baseline and showed greater increases in anxiety during the 
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post-challenge assessment and recovery period relative to baseline. Additionally, there 
was a significant time by group interaction for the panic groups; specifically, the linear 
decrease in anxiety during recovery was significantly steeper for nonsmokers with PD 
than for smokers with PD. This finding suggests a slower reduction in anxiety among 
smokers with PD as compared to nonsmokers with PD. Together, smoking among those 
with panic psychopathology seems to be associated with more severe panic symptoms.    
Summary of Smoking and Panic Literature 
Overall, research suggests that (1) smoking is more common among those with 
panic attacks and PD compared to the general population and vice versa (Breslau et al., 
1991; Goodwin et al., 2007; Lasser et al., 2000); (2) smoking typically precedes the 
onset of PD; (3) smoking increases the risk for developing panic problems (Johnson et 
al., 2000); and (4) smoking is associated with more severe panic symptoms among 
those with the disorder (Zvolensky, Leen-Feldner et al., 2004). These four lines of 
research suggest that daily smokers are an ―at risk‖ group for panic problems and 
prompt psychopathologists to explore the mechanisms underlying these associations.  
Anxiety Sensitivity and Smoking  
Anxiety sensitivity (AS).  Arguably, the most important individual difference 
factor relevant to the etiology of PD is AS, which reflects the fear of anxiety and anxiety-
related sensations (Reiss & McNally, 1985). AS is a dispositional, trait-like cognitive 
characteristic that is unique from the temperamental variables of trait anxiety (McNally, 
1996). This cognitive factor is theorized to predispose individuals to the development of 
panic problems (Reiss & Havercamp, 1996). For example, if a person perceives bodily 
sensations associated with autonomic arousal as a sign of imminent personal harm, this 
―high AS‖ individual is theorized to experience elevated levels of anxiety and to be at an 
increased risk for a panic attack. Research has strongly supported this line of theorizing: 
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(1) prospective studies with adolescents and adults indicate that AS predicts the future 
occurrence of panic attacks and worry about the future occurrence of such attacks 
(Schmidt, Lerew, & Jackson, 1997, 1999; Schmidt, Zvolensky, & Maner, 2006; Weems, 
Hayward, Killen, & Taylor, 2002); (2) AS is a significant predictor of responses to panic 
provocation procedures in the laboratory, even after controlling for negative affectivity 
(Zinbarg, Brown, Barlow, & Rapee, 2001); (3) AS is elevated among persons with a 
history of PD compared to those without the disorder (Taylor, Koch, & McNally, 1992); 
and (4) AS decreases with remission of panic psychopathology through intervention 
(Telch et al., 1993), and unlike many other panic risk factors (e.g., family history of PD), 
can therefore easily be targeted for therapeutic change in future intervention work. 
AS and smoking.   Several studies have examined the potential moderating role 
of AS in terms of the link between smoking and panic-relevant psychopathology, such 
that higher levels of AS may strengthen—or exacerbate—this association.  In one study 
of epidemiologically-defined (i.e., representative) adult residents of Moscow (n = 95 daily 
smokers from a larger sample of about 400 persons; Zvolensky, Kotov, Antipova, & 
Schmidt, 2003), AS moderated the effects of cigarettes smoked per day (M = 15) on 
level of agoraphobic avoidance. This significant interaction accounted for approximately 
10% of unique variance after controlling for their respective main effects and the 
theoretically-relevant factors of problematic alcohol use and negative affectivity. No 
interaction, however, was found for panic attacks, potentially due to the fact that 
assessment of this factor was restricted to the past (most recent) week to enhance the 
validity of panic reports (but probably truncating variability). Overall, these findings 
suggest smokers are not a homogeneous group in regard to their risk for panic problems 
and individual differences in AS may be key factors in accounting for such differences. 
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Moderating effects for AS also have been evident in between-group tests 
involving smokers and nonsmokers. For example, the combination of high levels of AS 
and a positive current smoking status predicted panic symptoms and somatic 
complaints, but not depressive symptoms in a biological challenge test (Leen-Feldner et 
al., 2007). Again, such findings suggest that AS (and possibly other factors) may 
moderate the relation between smoking and prototypical panic psychopathology 
variables (panic attacks and somatic complaints), even after controlling for gender and 
negative affectivity. Moreover, these associations are specific to panic-relevant 
processes. In a re-analysis of the Russian epidemiological study reported earlier, 
Zvolensky and colleagues extended this smoking and AS effect (Zvolensky, Kotov, 
Bonn-Miller, Schmidt, & Antipova, 2008). Here, AS again moderated the association of 
smoking status with indices of anxiety symptoms; effects were evident after controlling 
for the variance accounted for by alcohol use problems, environmental stress (past 
month), and gender. 
Prospective tests examining moderating factors in the tobacco use-panic relation 
are very limited. In the only study to date on this topic, McLeish, Zvolensky, and Bucossi 
(2007) evaluated the moderating role of AS in the relation between smoking rate and 
panic vulnerability variables among a community-based sample of 125 daily smokers (60 
women; Mage = 26.02 years). Findings indicate that the interaction between AS and 
smoking rate significantly predicted concurrent agoraphobic avoidance (3.2% of unique 
variance) and change in levels of anticipatory anxiety about bodily sensations during the 
3-month follow-up period (4.7% unique variance). Smokers high in AS who also smoked 
at greater rates reported the highest levels of avoidance and greatest increase in 
anticipatory anxiety. These data, in accord with cross-sectional findings (Leen-Feldner et 
al., 2007; Zvolensky, Kotov et al., 2003), once again, suggest that AS is an important 
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individual difference factor that, when coupled with higher rates of smoking, is 
associated with greater levels of avoidance and anticipatory anxiety among daily 
smokers, both of which contribute to the development of panic psychopathology. 
AS and smoking cessation.  In the earliest study in this domain, Brown, Kahler, 
Zvolensky, Lejuez, and Ramsey (2001) examined a subset of data from a randomized 
controlled clinical trial comparing standard smoking cessation treatment versus standard 
smoking cessation plus cognitive-behavioral treatment for depression in smokers with 
past major depressive disorder. In this investigation, the association between AS and 
relapse during the early stages of a quit attempt (e.g., first week), when individuals are 
most apt to experience symptoms of anxiety (Hughes, Higgins, & Hatsukami, 1990), was 
examined. AS was significantly associated with increased odds of lapsing during the first 
week after quit day (odds ratio = 2.0). Subsequent work has conceptually replicated and 
extended the results of Brown and colleagues (2001). For example, Zvolensky, Bonn-
Miller, Bernstein, and Marshall (2006) found AS was significantly associated with 
increased risk of early smoking relapse among a community sample of daily smokers; 
these effects were evident above and beyond smoking rate and negative affectivity. 
Such work has recently been extended to low-level smokers from Mexico, adding cross-
national empirical support (Zvolensky, Bernstein, Jurado, Colotla, Marshall, & Feldner, 
2007). Collectively, there is a growing amount of empirical evidence suggesting that 
panic psychopathology or pre-morbid panic-relevant variables, such as elevated AS, is 
related to early relapse problems, and possibly, lower rates of overall success in quitting.  
A closely related line of inquiry has suggested that AS is related to motivation to 
quit, barriers to quitting, and reasons for quitting. For example, Zvolensky, Baker, and 
colleagues (2004) found AS was related to higher levels of current motivation to quit 
smoking among adult daily smokers (Mage = 20.4, Mcigarettes per day = 10.2), and these 
17 
 
effects were not attributable to other theoretically-relevant factors (e.g., gender, smoking 
rate). These findings may at first seem counterintuitive in that it seems logical that 
individuals with high levels of AS would be less likely to express interest or motivation in 
quitting due to the feared negative consequences related to quitting (e.g., withdrawal 
symptoms, emotional dyscontrol). Yet, related work suggests that smokers who worry 
about the negative health-related effects of smoking may engage in more quitting 
behavior (Dijkstra & Brosschot, 2003). From this perspective, high AS smokers may be 
more apt to perceive a personal vulnerability to the negative effects of smoking (e.g., 
health risks), and as such, express greater motivation to quit (Zvolensky & Bernstein, 
2005) despite their greater difficulty in successfully doing so (Brown et al., 2001). In line 
with this reasoning, Zvolensky, Vujanovic, and colleagues (2007) more recently 
examined the relations between AS and (1) motivation to quit smoking, (2) barriers to 
smoking cessation, and (3) reasons for quitting smoking among 329 (160 women; Mage = 
26.08 years, SD = 10.92) adult daily smokers. After covarying for theoretically-relevant 
variables (negative affectivity, gender, axis I psychopathology, non-clinical panic attack 
history, number of cigarettes smoked per day, and current levels of alcohol 
consumption), AS was significantly incrementally related to level of motivation to quit 
smoking, as well as perceived barriers to quitting smoking. Additionally, after accounting 
for the variance explained by other theoretically relevant variables, AS was significantly 
associated with self-control reasons for quitting smoking (intrinsic factors), as well as 
immediate reinforcement and social influence reasons for quitting (extrinsic factors). 
These results provide empirical evidence that AS is uniquely related to level of 
motivation to quit smoking, perceived barriers to quitting, and certain intrinsic and 
extrinsic reasons for quitting. 
 AS and smoking motives.  Another facet of evidence in support of a smoking-
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panic relation is apparent from motivational and outcome expectancy research. In regard 
to smoking-related motivational processes, there is a large empirical literature 
documenting that smokers often attribute their smoking, at least in part, to its mood-
regulating functions and believe that smoking will reduce negative affect states (Parrott, 
1999). Due to their affective vulnerability, smokers with panic-relevant vulnerabilities 
(i.e., high AS) may be particularly motivated to smoke to escape from emotional distress 
elicited by acute nicotine withdrawal or non-withdrawal states (e.g., anticipatory anxiety; 
Zvolensky & Bernstein, 2005). A number of cross-sectional studies support this theory. 
Specifically, studies have indicated that AS is associated with coping-oriented smoking 
motives among young adults without a history of psychopathology (Novak, Burgess, 
Clark, Zvolensky, & Brown, 2003; Stewart, Karp, Pihl, & Peterson, 1997; Zvolensky, 
Bonn-Miller et al., 2006), adult clinical samples (Leyro, Zvolensky, Vujanovic, & 
Bernstein, in press), adolescents (Comeau, Stewart, & Loba, 2001), and individuals with 
a past history of major depression (Brown et al., 2001). Zvolensky, Feldner, Leen-
Feldner et al. (2004) reported conceptually similar findings for relations between AS and 
negative-reinforcement outcome expectancies for smoking. Furthermore, more recent 
studies have extended this work via the examination of the incremental validity of AS, 
examined concurrently with other theoretically-relevant cognitive and affective factors 
(i.e., perceived control, discomfort intolerance), in relation to coping-oriented smoking 
motives and negative reinforcement outcome expectancies (Gregor et al., in press; 
Leyro et al., in press). The Comeau et al. (2001) investigation, in particular, is 
noteworthy in that AS moderated the relation between trait anxiety (i.e., frequency of 
anxiety symptoms) and use of cigarettes to cope with affective distress, reporting a 
stronger relationship between anxiety and use of cigarettes to cope with negative 
emotions among high AS, compared with low AS, youth. Using a sample of PD patients, 
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Zvolensky, Feldner, Leen-Feldner, and colleagues (2005) also found that smokers with 
PD reported higher levels of smoking to reduce negative affect than their counterparts 
without such a history. These cross-sectional studies are not capable of elucidating the 
direction of the effects. Theoretically, coping-oriented smoking motives may have bi-
directional effects, influencing, and being influenced by, affective vulnerability. An initial 
investigation exploring this possibility was consistent with such an account (Gregor, 
Zvolensky, Bernstein, Marshall, & Yartz, 2007), reporting that coping-oriented motives 
were incrementally related to a variety of negative affective and cognitive factors.  
Nicotine Withdrawal and Panic Vulnerability 
One of the most striking aspects of nicotine use is that withdrawal symptoms (i.e., 
symptoms that emerge from a reduction of a specified drug in the body) are a prominent 
feature during the course of addictive use, and this has been conceptualized as a 
potential mechanism linking smoking to panic problems (Zvolensky, Schmidt, & Stewart, 
2003). Indeed, a large body of work has sought to explicate withdrawal symptoms 
across specific periods of time (Pomerleau, Pomerleau, & Marks, 2000) and to clarify the 
role of withdrawal symptoms in relapse (Hughes, 1992). Although the findings of studies 
addressing nicotine withdrawal symptoms are voluminous and diverse, it is evident that 
(1) nicotine deprivation among regular smokers produces a variety of prototypical 
withdrawal symptoms, including—but not necessarily limited to—irritability, restlessness, 
headaches, increased appetite, and sleep problems (Hughes, 2007a; Hughes & 
Hatsukami, 1986; Hughes et al., 1990); (2) negative affect is a central feature of such 
withdrawal (Baker, Piper, McCarthy, Majeskie, & Fiore, 2004; Patten & Martin, 1996, 
Piper & Curtin, 2006); and (3) there is a gradual emergence of withdrawal symptoms, 
with early signs occurring even after very short periods of time (e.g., minutes after the 
last cigarette smoked; Jarvik et al., 2000; Schuh & Stitzer, 1995). It is important to 
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remember in this context that while prolonged periods of withdrawal symptoms may be 
particularly distressing to individuals, relatively shorter periods of withdrawal (i.e., 60 to 
270 minutes) are the most frequent type of withdrawal-based experience in the day-to-
day lives of regular smokers (Hughes et al., 1990).  
 The aversive interoceptive cues that are a hallmark of nicotine withdrawal (both 
acute and prolonged) may have important implications for the study of panic vulnerability 
(Zvolensky, Schmidt, & Stewart, 2003). Specifically, the process of withdrawal from 
nicotine is characterized by an exacerbation of negative affect (e.g., anxiety, irritability) 
and other interoceptive symptoms (e.g., bodily tension; Hughes et al., 1990). Daily 
smokers experience repeated withdrawal episodes (varying in intensity and duration) on 
a daily basis and seemingly countless bouts of withdrawal over the course of their 
smoking careers. These withdrawal episodes represent potentially formative learning 
opportunities in the sense that the individual learns to associate internal and external 
stimuli with decreasing drug levels (O‘Brien, 1976). Indeed, regular smokers are attuned 
to detecting, often in an automatic fashion, even slight changes in drug levels and to 
associate them with increases in withdrawal symptoms (Baker et al., 2004); this 
perspective is supported by a large body of basic research on drug learning (Spencer, 
Yaden & Lal, 1988). 
Panic psychopathology or pre-morbid risk factors appear to be related to severity 
of acute nicotine withdrawal. In an early study in this domain, Breslau et al. (1991) found 
that tobacco withdrawal symptoms in a sample of young adults were significantly 
elevated among smokers with ―any anxiety disorder‖ compared to individuals without a 
history of such disorders; however, specific anxiety diagnoses were not provided, 
rendering unclear the specificity of such results to panic psychopathology per se. 
Zvolensky, Baker, and colleagues (2004) found that daily smokers with a history of panic 
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attacks reported significantly more intense anxiety-related withdrawal symptoms (i.e., 
anxiety, restlessness, difficulty concentrating, and irritability) compared to smokers 
without such a history; no differences were evident for the other tobacco withdrawal 
symptoms (e.g., increased appetite).  
Preliminary research utilizing biological challenge paradigms has yielded 
corroborating empirical evidence. For example, Zvolensky, Feldner, Leen-Feldner et al. 
(2005) evaluated the incremental validity of acute nicotine withdrawal symptoms (elicited 
by an average of two hours of nicotine deprivation) relative to negative affectivity, AS, 
and nicotine dependence in predicting anxious responding to a three-minute voluntary 
hyperventilation. The sample consisted of 90 regular smokers (46 females), as defined 
by smoking ≥ 10 cigarettes per day for at least one year, recruited through the general 
community. Consistent with prediction, greater levels of pre-challenge nicotine 
withdrawal symptoms uniquely predicted post-challenge intensity of panic symptoms and 
anxiety relative to other established factors. 
More recently, Abrams and colleagues (in press) examined 24 adult heavy 
smokers (10 females) in 12-hour nicotine withdrawal and 24 adult non-smokers (12 
females) on subjective and physiological reactivity to a 4-minute carbon dioxide (CO2) 
re-breathing challenge. Results indicate that, despite decreased respiration during the 
challenge, smokers experienced a significantly greater increase in self-reported panic 
symptoms than non-smokers. Additionally, smokers reported significantly greater trait 
levels of suffocation fear prior to the challenge.  
 Extrapolating from this research, interoceptive cues produced by nicotine 
withdrawal may serve to amplify anxious responding to evocative cues, particularly 
among highly anxiety sensitive individuals. This perspective is supported by numerous 
biological challenge studies which have shown that pre-challenge anxiety levels are a 
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consistent predictor of post-challenge anxiety and panic attack symptoms in the 
laboratory across different procedures and populations (Coplan et al., 1998). 
Additionally, if withdrawal symptoms are particularly strong, bodily sensations might be 
misappraised as personally dangerous (e.g., ―I‘m losing control‖), leading to a further 
intensification of anxiety symptoms and perhaps culminating in a panic attack. Through 
repeated withdrawal-specific learning experiences, certain smokers might develop 
hypervigilance to, and anxiety about, aversive interoceptive sensations.  
Conceptual Model: Integrating Research on Nicotine Withdrawal and AS 
Given that smoking-based withdrawal symptoms can elicit greater emotional 
vulnerability to fear-relevant stimuli (i.e., bodily sensations), it is logical to wonder why 
individuals would smoke if it increases their risk for such aversive anxiety experiences in 
the short-term and emotion-based psychopathology over the long-term (Johnson et el., 
2000). The partial answer to this question is likely related to the fact that smokers often 
use tobacco as a means of regulating their mood and coping with stress. Indeed, 
smokers tend to attribute their smoking to its alleged anxiolytic properties (Frith, 1971); 
reliably report higher frequencies of smoking behavior when anxious or emotionally 
distressed (Shiffman, 1993); and expect that smoking will help to reduce negative affect 
(Copeland, Brandon, & Quinn, 1995). Although smokers tend to perceive smoking 
behavior as an emotion regulatory strategy by which to reduce and manage negative 
affect, research findings do not necessarily support this perception (Baker et al., 2004). 
In fact, the perceived anxiolytic effects of smoking described by regular smokers seem to 
be reductions in acute nicotine withdrawal symptomatology (Parrot, 1999). A key finding 
that has emerged from this literature is that the effects of smoking on anxiety-related 
states are highly dependent on other factors related to affective processing (Kassel, 
1997). Specifically, research suggests that smoking-related effects associated with 
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emotional processing are largely indirect, as the variability in such effects is influenced 
by individual difference factors (Kassel, Stroud, & Paronis, 2003), such as AS. 
AS and nicotine withdrawal.  AS also may be critically important to PD 
vulnerability among smokers by serving to moderate the role of nicotine withdrawal on 
the development of panic-related processes. As described above, nicotine withdrawal 
elicits aversive interoceptive sensations. In this context, it is worth explicitly noting that: 
(1) individuals who regularly use drugs often cite unfavorable withdrawal experiences 
with such substances, which may serve as setting events for panic attacks (Aronson & 
Craig, 1986); and (2) among regular smokers, nicotine withdrawal (acute or prolonged), 
specifically, results in a variety of prototypical aversive internal cues that gradually 
emerge, and hence, are dynamic symptoms (Hughes & Hatsukami, 1986). These 
interoceptive stimuli may be perceived as personally threatening and unexpected among 
vulnerable persons, such as those high in AS. In particular, smoking-related withdrawal 
sensations may provide an opportunity for individuals to learn that physical sensations 
and other internal cues may be aversive and anxiety-provoking, and when coupled with 
individual differences in AS, contribute to a specific vulnerability to develop panic attacks 
and PD. Specifically, persons with high levels of AS should perceive interoceptive 
sensations as personally threatening and anxiety provoking. Therefore, the high AS 
individual experiencing bodily sensations related to nicotine withdrawal would be 
exposed to more frequent and intense aversive interoceptive learning trials. In this 
manner, smoking-related withdrawal cues are more likely to become phobic stimuli 
among individuals with elevated levels of AS (Bouton, Mineka, & Barlow, 2001). In 
contrast, individuals low in AS may be less susceptible to the panic-related effects of 
withdrawal because they are less fearful of internal sensations.  
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In regard to panic vulnerability, what is perhaps most clinically significant is that 
the combination of high AS and greater levels of acute nicotine withdrawal may place the 
individual at increased risk for anxious and fearful responding to internal cues (e.g., 
bodily sensations). That is, AS may increase the chance that more intense nicotine 
withdrawal symptoms will promote anxious and fearful responding to internal cues such 
as bodily sensations (please see Figure 1). In contrast, nicotine withdrawal may be less 
problematic for panic-relevant responding among low AS individuals. Thus, when a high 
AS smoker experiencing nicotine withdrawal symptoms is exposed to some evocative 
event that elicits bodily cues (whether expected or unexpected), he/she may be more apt 
to react to them in a panic-relevant fashion. Individual differences in AS may therefore 
moderate the intensity of nicotine withdrawal in regard to responding to internal cues 
with anxiety and fear. Theoretically, the moderator (i.e., AS) identifies the type of 
circumstances under which nicotine withdrawal has an effect on the panic outcome 
(Baron & Kenny, 1986). By contrast, AS would not be a mediator, as it does not 
necessarily explain why nicotine withdrawal affects panic symptoms. 
As reviewed above, in the only relevant study to date, Zvolensky, Baker et al. 
(2004) found that AS predicted the intensity of nicotine withdrawal during the first week 
of a most recent quit attempt among 127 regular smokers. Another prospective 
investigation found AS was related to elevated state anxiety during a quit attempt among 
adult daily smokers by one-month following cessation (Mullane, Stewart, Rhyno, 
Steeves, Watt, & Eisner, in press). These findings suggest that smokers high, relative to 
low, in AS are more likely to perceive interoceptive sensations that occur during nicotine 
deprivation (e.g., restlessness, anxiety, difficulty concentrating) as personally dangerous 
(e.g., ―I‘m going crazy‖) or  threatening (e.g., ―I‘m losing control‖).  Although this 
investigation did not test a moderating hypothesis per se, it does highlight an association 
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between AS and nicotine withdrawal, a pre-requisite to the above model. Given existing 
theory and these data, it is important to conduct a rigorous test of an AS moderator 
hypothesis in relation to the association of nicotine withdrawal to panic relevant 
responding, using a controlled laboratory paradigm. 
Overall Significance 
Data addressing anxiety-related individual difference variables among smokers 
that may relate to increased risk for developing PD are very limited. The absence of 
such information critically hinders efforts to: (1) understand the nature of the processes 
affecting the smoking-panic association; (2) better identify smokers with the highest 
susceptibility to panic-related problems; and thus (3) develop specialized prevention 
programs that can meaningfully target smoking and other panic risk factors. The present 
research has begun to fill these important gaps in the literature by examining the extent 
to which AS moderates the relation between level of nicotine withdrawal and fear 
responding to bodily sensations.  
Present Study: Aims and Hypotheses 
This investigation links theory and research on cognitive vulnerability for PD with 
smoking research on acute nicotine withdrawal to test the hypothesis that 
hypersensitivity to panic-relevant interoceptive cues (i.e., AS) moderates the role of 
nicotine withdrawal in relation to panic-relevant responding to a CO2 challenge among 
daily smokers. The CO2 challenge paradigm was selected for the present investigation 
because it can reliably produce bodily arousal and psychological symptoms relevant to 
panic states in both nonclinical and clinical samples (e.g., Zvolensky & Eifert, 2000).  
The specific aims of the present study were thus to test the hypothesis that AS 
moderates the relation between pre-challenge nicotine withdrawal states (i.e., random 
group assignment to Nicotine Deprivation, not smoking for 12 hours, or Non-Nicotine 
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Deprivation, smoking ‗as usual‘) and responding to a CO2 procedure (controlling for 
anticipatory anxiety, gender, number of axis I diagnoses, negative affectivity, and 
average daily smoking rate) as indexed by: (1) level of post-challenge anxiety focused 
on bodily sensations and intensity of panic attack symptoms; (2) skin conductance 
reactivity; and (3) level of behavioral avoidance of a future challenge.  Based upon the 
conceptual model delineated above, it was expected that individuals reporting higher 
levels of AS and undergoing nicotine deprivation (i.e., higher levels of nicotine 
withdrawal) would demonstrate the greatest levels of anxiety, panic-relevant responding, 
and skin conductance reactivity to the CO2 procedure as well as greater behavioral 
avoidance of a future challenge.  
Research Design and Methods 
Participants  
A total of 90 current (daily) smokers (35 women; Mage = 28.87, SD = 12.12, Range 
= 18-60 years) were examined for purposes of the current study. A total of 116 
participants provided informed consent to participate in the study and attended the first 
of two study appointments (please see Procedure: Overview section below). Of these 
116 participants, 3 participants reported quitting smoking immediately following the first 
appointment and were thus excluded from further participation; 3 participants were 
excluded on the basis of current or past psychotic-spectrum psychopathology; 1 
participant was excluded due to having decreased the number of daily cigarettes 
smoked by more than half in the past 6 months (please see inclusion/exclusion criteria 
below); 2 participants were excluded at the second session due to not passing 
biochemical verification tests of smoking status (carbon monoxide analysis of breath 
samples > 10 ppm; please see inclusion/exclusion criteria below); and 17 participants 
did not return for the second appointment and were not reachable by phone. Therefore, 
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a total of 26 participants did not complete participation in the entire study.  
A series of tests were conducted to assess differences between participants who 
did and did not complete participation in the study due to exclusion or self-
discontinuation. A chi square test was conducted, and the groups did not significantly 
differ in terms of gender [Χ2 (1, N = 116) = 1.85, p = .17]. A series of independent 
samples t-tests were then conducted, and the groups did not significantly differ on 
several key variables,1 including age [t(114) = -.34, p = .73], education level [t(111) = 
1.76, p = .08], marital status [t(111) = -1.54, p = .12], number of cigarettes smoked per 
day [t(112) = -1.33, p =.18], or number of smoking years [t(113) = -1.06, p = .28]. All the 
following information is based on the 90 participants who completed both sessions of the 
study.  
The racial composition of the sample was consistent with that of the state of 
Vermont population (State of Vermont Department of Health, 2007): approximately 
93.3% of the sample identified as white/Caucasian, 2.2% identified as black/African-
American, 2.2% identified as Hispanic/Latino, and 2.2% identified as ―other.‖  In terms of 
educational status, 2.2% of participants received less than a high school education, 
32.2% of participants completed high school or passed a General Educational 
Development (G.E.D.) test, 47.8% of participants completed some college or were 
currently enrolled in college, 13.3% of participants completed college, 3.3% of 
participants completed some graduate coursework, and 1.1% of participants (n = 1) held 
a graduate degree. With regard to current marital status, 78.9% of participants reported 
being single, 6.7% reported being married, 5.6% reported being divorced, 7.8% reported 
being separated from their spouse/partner, and 1.1% reported being widowed. 
At the first appointment, smoking status was verified using carbon monoxide 
(CO) analysis of breath samples, and participants evidenced a mean rating of 18.10 (SD 
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= 12.09), indicating regular smoking (CO ppm >10). Participants reported smoking an 
average of 15.67 (SD = 8.22) cigarettes per day and smoking for an average of 11.16 
(SD = 10.88) years. Participants reported initiating daily smoking at a mean age of 17.47 
(SD = 5.20) years. A mean low to moderate level of nicotine dependence was reported 
(M = 3.40, SD = 1.93). In terms of cessation, participants reported an average of 2.53 
(SD = 2.40) quit attempts, with a mean of 3.86 (SD = 6.39) occasions of at least 12-hour 
abstinence.  
Approximately 77.7% of participants reported drinking alcohol, and on average, 
these individuals endorsed drinking 2 to 4 times per month and consuming 3 or 4 drinks 
on occasion. More specifically, approximately 18.9% of participants endorsed drinking 
alcohol at the frequency of monthly or less, 16.7% endorsed drinking 2 to 4 times per 
month, 28.9% reported drinking 2 to 3 times per week, and 13.3% reported drinking 4 or 
more times per week. Participants scored a mean of 9.91 (SD = 7.04) on the Alcohol 
Use Disorders Identification Test (AUDIT; Babor, De La Fuente, Saunders, & Grant, 
1989, 1992), with 54.4% of participants meeting criteria for at least moderate alcohol 
problems, as indexed by a score of 8 or higher on the AUDIT. In terms of marijuana use, 
approximately 51.1% of participants reported using marijuana on at least one occasion 
in the past 30 days. Approximately 41.1% of the sample reported using marijuana at 
least weekly during the past month, and specifically, 10% of participants endorsed using 
marijuana on 1 to 3 occasions in the past month, 21.1% endorsed using marijuana on 4 
to 7 occasions in the past month, and 20.0% reported using marijuana more than once 
per day.  
In regard to axis I psychiatric diagnoses -- excluding substance use disorders 
which were not assessed -- 32.2% of participants met criteria for current (past month) 
Diagnostic and Statistical Manual of Mental Disorders – 4th Edition, Text Revision (DSM-
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IV) axis I psychopathology. Of participants with current axis I psychopathology, 13.3% 
met criteria for one axis I diagnosis, 11.1% met criteria for two axis I diagnoses, and 
7.8% met criteria for three axis I diagnoses. A total of 15 participants met criteria for 
generalized anxiety disorder, 12 participants met criteria for major depressive disorder, 8 
participants met criteria for social phobia, 7 participants met criteria for specific phobia, 6 
participants met criteria for panic disorder with or without agoraphobia, 2 participants 
met criteria for posttraumatic stress disorder, 1 participant met criteria for obsessive 
compulsive disorder, 1 participant met criteria for agoraphobia, 1 participant met criteria 
for dysthymia, and 2 participants met criteria for bipolar disorder.  
 Adult regular smokers interested in the investigation were screened by phone for 
study eligibility. For inclusion in the study, participants (1) were between 18 and 65 years 
of age; (2) were daily smokers for at least the past year; (3) were currently (past month) 
smoking at least 10 cigarettes per day; (4) had not decreased the number of cigarettes 
smoked per day by more than half in the past 6 months; and (5) reported a willingness to 
abstain from smoking for a 12-hour period, as determined by CO analysis of breath 
samples (10 ppm cutoff; Cocores, 1993). Participants were excluded from the study 
based on evidence of: (1) limited mental competency and the inability to give informed, 
voluntary, written consent to participate; (2) current or past psychotic-spectrum 
symptomatology; (3) current (past week) suicidal intent; (4) for women, the possibility of 
being pregnant (by self-report); and (5) current or past chronic illness (e.g., heart 
disease, chronic obstructive pulmonary disease). Individuals with a history of panic 
attacks and PD were not excluded, since nicotine withdrawal may exacerbate panic-
relevant responding even among individuals with panic attacks and PD, thus serving to 
maintain the panic-related conditions over time. These screening criteria were 
successfully used in previous studies involving CO2 administration (Zvolensky, Eifert, & 
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Lejuez, 2001) and were assessed by a validated medical history screening interview 
developed explicitly for this purpose (Forsyth & Eifert, 1998). Upon request, all 
individuals meeting psychiatric exclusionary criteria were referred to the department 
clinic that is housed in the same building as our laboratory.  
Procedure: Overview 
Data collection for the study was conducted over a period of 12 months. 
Participant retention, differential dropout, and follow-up. The study consisted 
of two appointments, averaging 2 hours and 45 minutes in length, respectively.  The 
mean duration of time between appointments was 6 days (SD = 3.93, Range = 1-19 
days). Participants were compensated a total of $35 for participating in the entire study 
and were paid based on their length of involvement in the study.  To reduce attrition, 
participant payments were back-loaded such that participants received $10 at the 
completion of the first session and $25 at the conclusion of the second session. Only 
participants who met eligibility requirements, as determined by the interview screening at 
the first session, were scheduled for the second session. This compensation schedule 
was intended to decrease the probability of attrition by offering adequate reward 
incentives for the completion of both phases of the study. In addition, eligible participants 
received telephone reminders 24 hours prior to their second scheduled appointment to 
confirm appointment times and to provide any necessary clarification of protocol (i.e., 12-
hour abstinence from smoking for the nicotine deprivation – CO2 group). Please see 
Figure 2 for an outline of the study procedure. 
 Screening and group assignment. Smokers were recruited through newspaper 
advertisements and flyers posted in local businesses and on community bulletin boards. 
Recruitment ads stated, ―Are you a smoker? Would you be willing to stop smoking for 12 
hours?‖ Persons responding to study advertisements were first contacted via telephone, 
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screened to ensure that basic inclusionary criteria were met (see above), and scheduled 
for a visit, if deemed appropriate. Potentially eligible persons (e.g., smoking ≥ 10 
cigarettes per day) were invited to the laboratory to complete the baseline assessment 
session.  
At the baseline session, participants completed informed verbal and written 
consent and then were administered a complete diagnostic interview, a validated 
medical screening interview, and CO analysis of breath samples. If eligible after these 
procedures, stratified random assignment procedures were utilized to assign participants 
to either the (1) Nicotine Deprivation – CO2 or (2) Non-Nicotine Deprivation – CO2 
condition (i.e., smoking as usual). Eligible participants were given a battery of self-report 
questionnaires to complete between appointments and return at the second session. 
The second session was scheduled at the conclusion of the baseline session for a date 
within 2 weeks of the baseline assessment. At the end of the first visit, participants were 
compensated $10. 
At the conclusion of the first appointment, participants were informed as to 
whether or not to refrain from smoking for 12 hours prior to their next scheduled 
appointment. All participants were instructed to not use any form of nicotine replacement 
therapy for the duration of their involvement in the study; and this information was 
verbally verified at both study appointments. Specifically, participants in the Nicotine 
Deprivation group were asked to refrain from smoking for 12 consecutive hours prior to 
their second scheduled appointment, which consisted of the CO2 administration 
component. The 12-hour nicotine deprivation interval was standardized so that all 
participants were instructed to refrain from smoking for 12 hours overnight; second 
session visits were scheduled during the morning hours relevant to the participants‘ 
stated 12-hour deprivation interval (i.e., individuals scheduled their appointments for 
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morning time slots that reflected their particular 12-hour overnight deprivation schedule). 
The 12-hour period of deprivation and its standardization were based upon past work 
that has suggested (1) it produces meaningful variability in symptom level and profiles 
(Hughes et al., 1990); (2) it is a common experience for acute withdrawal and hence a 
good model for the present study; and (3) it is feasible at a practical level for carrying out 
this protocol. For example, in a recent study, a 12-hour period of smoking abstinence 
was used to elicit nicotine withdrawal symptoms among 45 daily smokers (M. J. 
Zvolensky, personal communication, January 15, 2005). In all cases, it is expected that 
future work can build upon this study and extend the withdrawal deprivation to greater 
periods of time. Individuals in the Non-Nicotine Deprivation group were told to smoke as 
normal, and information on their actual use of nicotine during this 12-hour interval was 
obtained via self-report and CO analysis of breath samples.  
 Trained research assistants placed phone calls to all participants 24 hours prior 
to their second appointments to ensure (1) that participants were reminded of their 
appointments, and (2) that participants in the Nicotine Deprivation group remembered to 
abstain from smoking for 12 hours prior to their scheduled session. Upon arrival to the 
laboratory for the second session, participants in the Nicotine Deprivation group again 
completed CO analysis of breath samples to biochemically verify smoking abstinence. 
Participants assigned to this group who had not refrained from smoking did not complete 
the laboratory session; they were dropped/replaced from the study. Participants in the 
Non-Nicotine Deprivation group were asked to smoke ―as usual‖ prior to returning to the 
laboratory for a second appointment to undergo the CO2 challenge. Upon returning to 
the laboratory, they were asked to smoke one cigarette 15 minutes prior to the 
laboratory session, which was visually verified by a trained research assistant, to ensure 
an absence of nicotine deprivation. Participants in this group also were asked to 
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biochemically verify smoking status (i.e., non-abstinence) via completion of CO analysis 
of breath samples.  Since the current investigation examined the effects of nicotine 
withdrawal rather than the effects of nicotine exposure, nicotine exposure 
standardization (i.e., use of standardized cigarettes) relevant to the Non-Nicotine 
Deprivation group was not warranted.  
Pre-Challenge Measures 
Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Diagnostic 
assessments were conducted using the SCID-I-NP (non-patient version; First, Spitzer, 
Gibbon, & Williams, 1995). The SCID-I-NP version was used because participants in the 
study were not identified as psychiatric patients. Consistent with past work in this 
domain, only the mood, psychosis, and anxiety sections of the SCID-I-NP were 
administered for purposes of the present study (e.g., McLeish et al., 2007). The DSM-IV 
version of the SCID-I has been shown to have good reliability (inter-rater Kappa = .63 – 
1.0, Zanarini et al., 2000; test-retest Kappa = .44 - .78, Zanarini et al., 2000) and good to 
excellent validity (Basco et al., 2000); and the SCID-I is generally regarded as the ―gold 
standard‖ in diagnostic interviewing (Shear et al., 2000). All SCID-I interviews (100%) 
were administered by the Principal Investigator of this project and supervised by the 
faculty advisor. Interviews were audio-taped and the reliability of a random selection of 
20.6% of interviews (n = 24) was determined and checked for accuracy by a doctoral-
level independent rater; no cases of (diagnostic coding) disagreement were noted.  
Anxiety Sensitivity Index (ASI). To assess sensitivity to, and discomfort with, 
anxious arousal, the 16-item ASI (Reiss, Peterson, Gursky, & McNally, 1986) was 
employed. The ASI is a self-report measure on which respondents indicate, on a 5-point 
Likert-style scale (0 = very little to 4 = very much), the degree to which they fear the 
potential negative consequences of anxiety-related symptoms and sensations. The ASI 
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is scored as a single sum across all items, and the total score may range from 0 to 64. 
The ASI has high internal consistency, ranging from .84 for a sample of college students 
with arachnophobia (i.e., fear of spiders) to .88 -.90 for a clinical sample of anxiety-
disordered patients (Reiss et al., 1986). The ASI has demonstrated good test-retest 
reliability (kappa = .75) as well as excellent convergent validity (r > .70) with other 
established anxiety-relevant measures (Peterson & Reiss, 1992; Zinbarg, Mohlman, & 
Hong, 1999). The ASI is unique from, and demonstrates incremental predictive validity 
to, trait anxiety (McNally, 1996). The ASI is made up of one higher-order factor (ASI 
Total Score) and three lower-order factors: Physical, Psychological, and Social 
Concerns (Zinbarg, Barlow, & Brown, 1997). In the present investigation, as in past work 
(Zvolensky, Kotov et al., 2003), the total ASI score was utilized, as it represents the 
global AS factor and therefore reflects the different types of lower-order fears. 
Positive Affect Negative Affect Scale (PANAS). The PANAS (Watson, Clark, & 
Tellegen, 1988) is a 20-item measure on which respondents indicate, on a 5-point Likert-
type scale (1 = Very slightly or not at all to 5 = Extremely), the extent to which they 
generally feel different feelings and emotions (e.g., ―Hostile‖). The PANAS is a well-
established measure commonly used in psychopathology research (Watson et al., 
1988). Factor analysis indicates that it assesses two global dimensions of affect: 
negative and positive. Both subscales of the PANAS have demonstrated good 
convergent and discriminant validity. Additionally, both the negative affectivity and the 
positive affectivity scales of the PANAS have demonstrated high levels of internal 
consistency across a range of populations, including cross-national samples (range of 
alpha coefficients: .83 - .90 and .85 - .93, respectively; see Watson, 2000). The PANAS 
has also demonstrated good reliability (r = .71) (Watson et al., 1988). Only the negative 
affectivity scale (PANAS-NA) was used in the present study.   
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 Smoking History Questionnaire (SHQ). Smoking history and pattern were 
assessed with the well-established SHQ, which includes items pertaining to smoking 
rate, age of onset, and years of regular smoking. The SHQ has been successfully used 
in previous studies as a descriptive measure of smoking history (Brown, Lejuez, Kahler, 
& Strong, 2002; Zvolensky, Lejuez, Kahler, & Brown, 2004). In the present study, the 
SHQ was used to determine all smoking-relevant history characteristics (e.g., daily 
smoking rate, number of past quit attempts). Since the SHQ is a descriptive measure, 
information regarding its psychometric properties is not relevant or available. 
Fagerstrom Test for Nicotine Dependence (FTND). The FTND is a 6-item 
scale designed to assess gradations in tobacco dependence (Heatherton, Kozlowski, 
Frecker, & Fagerstrom, 1991). Two items are rated on a four-point Likert-style scale (0-
3); and four items are rated dichotomously (yes/no). Sample items include, ―How soon 
after you wake up do you smoke your first cigarette?‖ and ―Do you find it hard to refrain 
from smoking in places where it is forbidden?‖ The FTND is a revision of the Fagerstrom 
Tolerance Questionnaire (FTQ; Fagerstrom, 1978). The FTND has shown good internal 
consistency, positive relations with key smoking variables (e.g., saliva cotinine; 
Heatherton et al., 1991; Payne, Smith, McCracken, McSherry, & Antony, 1994), and high 
degrees of test-retest reliability (Pomerleau, Carton, Lutzke, Flessland, & Pomerleau, 
1994).  
Minnesota Nicotine Withdrawal Scale (MWS). The MWS (Hughes & 
Hatsukami, 1986) is a reliable and sensitive 7-item self-report scale that was utilized to 
measure current nicotine withdrawal symptoms. On the MWS, participants are asked to 
rate their nicotine withdrawal symptoms on a 4-point Likert-type scale (0 = not present to 
3 = severe). As recommended by Hughes and Hatsukami (1998), only DSM-IV 
withdrawal symptom items were included in the computation of the MWS total score. 
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The MWS was administered at the second session at three distinct time-points, spaced 
approximately 8-10 minutes apart: pre-challenge (immediately upon arrival to the 
laboratory), minute 9 of pre-challenge baseline, and post-challenge (approximately at 
minute 3 post-challenge). Pre-challenge ratings, indexed upon arrival to the laboratory, 
were used to verify group differences in withdrawal symptoms as per the between-group 
manipulation check. 
Alcohol Use Disorders Identification Test (AUDIT; Babor et al., 1989, 1992). 
The AUDIT is a 10-item self-report screening measure developed by the World Health 
Organization to identify individuals with alcohol problems (Babor et al., 1989, 1992). 
There is a large body of literature attesting to the validity of the AUDIT (Saunders, 
Aasland, Babor, De La Fuente, & Grant, 1993). In the present study, the total score was 
computed to measure alcohol use problems (Babor et al., 1989, 1992), and the 
frequency and quantity of use items were used to determine patterns of alcohol use 
among the sample.  
Marijuana Smoking History Questionnaire (MSHQ; Bonn-Miller & Zvolensky, 
2005). The MSHQ was used to assess marijuana use history and pattern. The MSHQ is 
a self-report instrument that includes items pertaining to marijuana smoking rate (lifetime 
and past 30 days), age of onset at initiation, years of being a regular marijuana user, and 
other descriptive information. The MSHQ has been employed successfully in past 
research (e.g., Bonn-Miller, Zvolensky, Leen-Feldner, Feldner, & Yartz, 2005; Zvolensky, 
Bonn-Miller, Bernstein, McLeish, Feldner, & Leen-Feldner, 2006).  In the present study, 
the item relevant to past 30-day marijuana use was utilized to determine patterns of 
recent marijuana use among the sample. Since the MSHQ is a descriptive measure, 
information regarding its psychometric properties is not relevant or available. 
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Carbon Monoxide (CO) Analysis.  A noninvasive biochemical verification of 
smoking history was completed by CO analysis of breath samples (10 ppm cutoff; 
Cocores, 1993). Expired air CO levels were assessed using a CMD/CO Carbon 
Monoxide Monitor (Model 3110; Spirometrics, Inc.).  
Challenge Measures 
 Subjective Units of Distress Scale (SUDS). SUDS ratings (Wolpe, 1958) were 
used to index self-reported anxiety focused on bodily sensations. This Likert-type scale 
ranges from 0 (no anxiety) to 100 (extreme anxiety). Participants completed these scales 
before the challenge procedure as an index of anticipatory anxiety, during the challenge 
procedure (at one-minute intervals), and immediately after the challenge as an index of 
maximum anxiety focused on bodily sensations.  
 Diagnostic Sensations Questionnaire (DSQ). The DSQ (Sanderson, Rapee, & 
Barlow, 1988, 1989) was used to assess DSM-IV panic attack symptoms immediately 
post-challenge. This measure is frequently employed in challenge work (Zinbarg et al., 
2001; Zvolensky, Eifert, Lejuez, & McNeil, 1999). Ratings for the DSQ are made on a 9-
point Likert-type scale (0 = not at all to 8 = very strongly felt). The DSQ, specifically, lists 
DSM-IV panic symptoms and yields composite scores for a mean intensity level for 
cognitive (e.g., fear of going crazy) and physical (e.g., breathlessness or smothering 
sensations) symptoms. Past work has used these symptom composites in laboratory 
challenge studies (Forsyth, Eifert, & Canna, 2000; Schmidt, Forsyth, Santiago, & 
Trakowski, 2002); the panic symptom composites (i.e., physical symptoms, cognitive 
symptoms) shared only 30% of variance with one another, indicating that they were 
tapping distinct but related aspects of panic-related symptoms (Zvolensky, Leen-Feldner 
et al., 2004).  
38 
 
 Post-Challenge Avoidance Measure. In order to index behavioral avoidance 
post-challenge, participants‘ willingness to participate in another CO2 administration was 
evaluated by a one-item self-report questionnaire. This item asked participants to rate 
their levels of willingness to participate in another CO2 administration study. Specifically, 
participants were told that other CO2 studies will be recruiting individuals for participation 
within the next 2 weeks. Then, participants were asked to indicate their willingness to 
participate on a 100-point Likert-style questionnaire intended to assess participants‘ 
interest in returning for another CO2 investigation (0 = no desire to participate; 100 = 
definite desire to participate).  This type of index has been utilized successfully in the 
past (Eifert & Heffner, 2003).  
Laboratory Challenge Methodology 
For purposes of this study, the CO2-inhalation paradigm (Forsyth & Eifert, 1998; 
Zvolensky & Eifert, 2000; Zvolensky, Eifert et al., 1999) was utilized as the panic-
relevant challenge procedure because it can be safely employed, its parametric 
properties are well studied, and it can reliably produce bodily arousal and psychological 
symptoms relevant to panic states in nonclinical and clinical samples (see Zvolensky & 
Eifert, 2000, for a review). Moreover, it has been safely and effectively used in previous 
work with adults across numerous research sites without adverse incident for decades 
(e.g., Gorman et al., 2001). The advantages of using this challenge tactic are several 
and include: (1) its ability to produce reliable psychological and autonomic responses 
that resemble those seen clinically in patients with PD; (2) the ability to safely and 
carefully control its administration (i.e., timing and duration); (3) the fact that it is a 
noninvasive, reliable, and well-investigated provocation, with known parameters; and (4) 
that it functions effectively to produce clinically-relevant responses that escalate rapidly 
within several seconds and that remit quickly.  
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Laboratory procedure.  At the second scheduled session, each participant was 
introduced to a controlled laboratory setting with intercom and auditory communication 
with the experimenter in the adjacent room. Via a television monitor that was connected 
to two cameras in the experiment room, the experimenter maintained audio-visual 
monitoring of each participant. The Principal Investigator or a trained research assistant 
attached psychophysiological monitoring electrodes and a C-Pap respiratory mask to 
each participant. Participants listened to a standardized audio-taped description of the 
challenge procedure, successfully used in past work to equate expectancy effects 
(Feldner, Zvolensky, Eifert, & Spira, 2003; Spira, Zvolensky, Eifert, & Feldner, 2004). 
The audio-taped directions informed participants that breathing CO2- enriched air might 
produce several transitory sensations (e.g., dizziness), but no adverse long-term effects 
(Harrington, Schmidt, & Telch, 1996).  During the session, participants sat alone in the 
experiment room. The description of the procedure was as follows: 
“During the study, you will receive several inhalations of CO2-enriched air that 
may produce physical and mental sensations associated with bodily arousal. You 
may feel your heart racing, your palms might be sweaty, you might feel dizzy, 
and you might have some breathing problems. However, there will be no adverse 
long-term effects resulting from the inhalations.” 
 There were three main recording phases during the challenge. The first phase 
consisted of a 10-minute pre-challenge baseline. The second phase involved a computer 
automated CO2 biological challenge (see Lejuez, Forsyth, & Eifert, 1998), a commonly 
employed tactic that effectively elicits fear responses (Zvolensky & Eifert, 2000). For 
both the Nicotine Deprivation and Non-Nicotine Deprivation groups, the challenge 
paradigm consisted of a single 4-minute 10% CO2-enriched air provocation. The third 
phase consisted of a 5-minute post-challenge recovery period; and participants 
40 
 
completed a set of self-report measures (see above). Then, participants were debriefed 
and compensated $25. 
 Laboratory physiological measures. A J&J Engineering I-330-C2 system was 
used to digitally record physiological data on-line at a sample rate of 1024 samples per 
second across all channels using J&J Engineering Physiolab Software. Skin 
conductance reactivity data, which has been shown to effectively discriminate high and 
low AS individuals in past stress induction challenge work (e.g., Stewart & Pihl, 1994), 
was assessed in micromhos by using a Coulbourn S71-23 isolated skin conductance 
coupler.  Disposable Ag/AgCl electrodes were placed in a standard bilateral 
configuration on the palmar side of each wrist and on the first fingers of the non-
dominant hand. Respiration rate (breaths-per-minute) was sampled using a Pnemograph 
sensor cable with two elastic PS-2 sensors filled with conductive fluid. Stretching across 
the sensors causes a voltage change, thereby providing a measure of excursion of the 
chest during respiration. Physiological responsiveness was assessed continuously 
throughout all study phases.   
 Apparatus.  Experimental sessions were completed in an 8 ft. x 10 ft. sound 
attenuated room, containing a chair, desk, Pentium-III microcomputer, SVGA color 
monitor, mouse, and keyboard, located in the Department of Psychology at the 
University of Vermont. Audio-visual monitoring allowed participants to communicate with 
the experimenter in the adjacent room. The experimenter room contains 10% CO2 
compressed air enclosed in a 40-cylinder gas tank, a one-way mirror, and a Coulbourn 
Modular recording device read through a Pentium microcomputer. A one-way mirror and 
video camera allowed experimenters to directly observe session events. The challenge 
was a single 4-minute administration of 10% CO2-enriched air (10% CO2, 21% O2, 69% 
N2); this time period has previously been successfully employed (Feldner et al., 2004). 
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The 10% CO2 is a validated dosage, as indexed by pCO2, arousal indices, and self-
reported distress (Zvolensky & Eifert, 2000). Participants were equipped with a 
continuous positive pressure Downs C-Pap Mask. The CO2 is stored in a 101 cm 
cylinder and fed through a 5 cm X 5 cm hole via aerosol tubing from the experimenter 
room to a positive-pressure downs C-Pap mask worn by participants. An automated and 




The main and interactive relations between AS and nicotine withdrawal were 
evaluated in relation to responding to the CO2 challenge using a hierarchical multiple 
regression procedure (Cohen & Cohen, 1983). Squared semi-partial correlations (sr2) 
were used as indices of effect size in all models and were tested at a two-tailed alpha of 
.05 (Tabachnick & Fidell, 2007). Main effect variables were mean-centered prior to 
computing product terms (Aiken & West, 1991). Consistent with past research in this 
area (Schmidt, Lerew, & Joiner, 2000), separate models were constructed for predicting 
each of the dependent variables. Alpha level was corrected using a Bonferroni 
procedure to control for family-wise error, and since a total of four hierarchical regression 
analyses were proposed, alpha was set to .0125 (.05/4 = .0125). This analytic approach 
provided a test of incremental validity and ensured that any observed effects for the 
interaction term are separable from the variance accounted for by the other theoretically-
relevant factors at levels one or two in the equation (Cohen & Cohen, 1983). Based on 
recommendations of Cohen (1988), the form of significant interactions, if applicable, was 
examined by inserting specific values for each predictor variable (one standard deviation 
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above and below the mean for AS) into the regression equations associated with the 
described analysis. 
It is noteworthy that AS was conceptualized on an a priori basis as a variable that 
would affect the relation between nicotine withdrawal and panic responsivity (i.e., a 
moderator variable), rather than account for the relation (i.e., mediator variable; 
Holmbeck, 1997). That is, given evidence of a direct association between nicotine 
withdrawal and panic responsivity (Zvolensky, Baker, et al., 2004), AS was hypothesized 
to maintain a significant association with panic vulnerability even after accounting for 
variance attributable to nicotine withdrawal and panic symptoms. Therefore, AS was not 
conceptualized as a mediator in this particular study (Baron & Kenny, 1986).  
Hypothesis Testing  
Hypothesis 1.  To address hypothesis 1, two hierarchical multiple regression 
analyses were performed. For these analyses, predictor variables were divided into 
three levels in the hierarchy: (1) anticipatory anxiety (baseline SUDS rating; recorded at 
minute 9 of pre-challenge baseline), gender, number of axis I diagnoses, negative 
affectivity, and average daily smoking rate were entered at level one; (2) mean-centered 
main effect for AS (ASI total score) and withdrawal group status (Nicotine Deprivation vs. 
Non-Nicotine Deprivation; dichotomous variable) were simultaneously entered into the 
model as a set at level two; and (3) the interaction term for AS (mean-centered) and 
withdrawal group status were entered at level three. The dependent variable for the first 
hierarchical multiple regression analysis was level of anxiety focused on bodily 
sensations (post-challenge SUDS ratings; recorded during minute 1 post-challenge), and 
the dependent variable for the second analysis was intensity of panic attack symptoms 
(DSQ total composite score). The DSQ composite score was used, as it includes both 
physical and cognitive symptoms and therefore is a robust index of panic-relevant 
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responding and the most inclusive way to examine associations with panic-related 
symptom intensity reporting (Zvolensky & Eifert, 2000). Based upon this conceptual 
model, it was expected that those individuals reporting higher levels of AS and randomly 
stratified to the Nicotine Deprivation group would demonstrate the greatest level of 
panic-relevant responding to the CO2 procedure.   
 Hypothesis 2.  To address hypothesis 2, one hierarchical multiple regression 
analysis was performed; the dependent measure was a composite (average) 
physiological variable of skin conductance reactivity readings taken at one-minute 
intervals during the CO2 challenge. As previously discussed, skin conductance levels 
have effectively discriminated high and low AS individuals in past stress-induction 
challenge work (e.g., Stewart & Pihl, 1994). At level one, anticipatory anxiety (baseline 
skin conductance level; recorded at minute 9 of pre-challenge baseline), gender, number 
of axis I diagnoses, negative affectivity, and average daily smoking rate were entered at 
level one as covariates. At level two, the mean-centered main effect for AS (ASI total 
score) and withdrawal group status (Nicotine Deprivation vs. Non-Nicotine Deprivation; 
dichotomous variable) were simultaneously entered. At level three, the mean-centered 
interaction term for AS and withdrawal group status was entered. Based upon the 
conceptual model, it was expected that individuals reporting higher levels of AS and 
randomly stratified to the Nicotine Deprivation group would demonstrate the greatest 
level of skin conductance reactivity (i.e., change from baseline to overall levels during 
the challenge). This approach to data analysis of physiological variables is consistent 
with past challenge work on anxiety (Zvolensky & Eifert, 2000).  
Hypothesis 3.  To address hypothesis 3, one hierarchical multiple regression 
analysis was performed. For this analysis, predictor variables were divided into three 
levels in the hierarchy in a manner identical to that proposed for hypothesis 1. The 
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dependent variable for the regression analysis was level of avoidance of a future CO2 
procedure (Post-Challenge Avoidance Measure). Based upon the conceptual model, it 
was expected that individuals reporting higher levels of AS and randomly stratified to the 
Nicotine Deprivation group would demonstrate the greatest level of avoidance of a future 
challenge (i.e., least amount of interest in completing another CO2 procedure in the 
future).   
Results 
Descriptive Analyses 
 Please see Table 1 for a summary of participant characteristics as a function of 
withdrawal group status (Nicotine Deprivation vs. Non-Nicotine Deprivation). Two chi-
square analyses (dichotomous variables: gender and psychotropic medication use) and 
a series of independent samples t-tests were conducted to assess differences between 
the nicotine deprivation conditions, and groups were compared in terms of 
characteristics including gender, psychotropic medication use, age, education level, 
number of axis I diagnoses (SCID-I-NP), negative affectivity (PANAS), average daily 
smoking rate (SHQ), daily smoking rate during the past week (SHQ), age onset of daily 
smoking (SHQ), number of daily smoking years (SHQ), nicotine dependence level 
(FTND-total), alcohol use problems (AUDIT-total), past 30-day marijuana use, AS (ASI-
total), anticipatory anxiety (pre-challenge SUDS ratings, recorded at minute 9 of pre-
challenge baseline/1 minute pre-challenge), peri-challenge anxiety (SUDS ratings 
recorded at one-minute intervals during the challenge), post-challenge anxiety (SUDS 
ratings recorded during minute 1 post-challenge), and latency to mask pulling (minutes) 
and discontinuation of challenge procedure.2 
 Significant differences between groups were found in terms of age, number of 
daily smoking years, and nicotine withdrawal symptoms (pre-challenge). The Non-
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Nicotine Deprivation group was significantly older [t(88) = -2.29, p < .05] and reported 
smoking for a higher number of years [t(87) = -2.53, p < .05] than the Nicotine 
Deprivation group. As expected, the Nicotine Deprivation group endorsed significantly 
higher levels of nicotine withdrawal symptoms than the Non-Nicotine Deprivation group 
[t(87) = 2.66, p = .009]. 
Data Reduction Approach and Manipulation Checks of Challenge Paradigm 
After screening for outliers due to sampling error (e.g., participant movement), 
the integrity of the 10% CO2 – enriched air laboratory challenge paradigm was 
examined. Standard data reduction strategies employed in past biological challenge 
work were employed for the physiological data screening and reduction process 
(Zvolensky, Lejuez, & Eifert, 1998); specifically, any non-readable data (e.g., missing 
data due to human error, such as an electrode falling off a participant) were eliminated. 
The data also were inspected for falling within an expected range, per the 
recommendations of Venables and Christie (1980). If data were at an extreme (e.g., 
heart rate greater than 230 beats per minute), they were removed due to the likelihood 
of containing a potential sampling error.  
Please see Table 2 for descriptive data and group comparisons in terms of 
dependent measures pre- (minute 9 of pre-challenge baseline) to post-challenge (minute 
1 post-challenge). Within the total sample, SUDS anxiety ratings, skin conductance 
level, heart rate, and respiration rate all significantly increased from pre- to post-
challenge. When the Nicotine Deprivation and Non-Nicotine Deprivation groups were 
examined independently, this pattern was maintained with one notable exception: The 
Nicotine Deprivation group did not report significantly greater levels of anxiety (SUDS 




 Please see Table 3 for a summary of all zero-order correlations and descriptive 
data for all theoretically-relevant variables. 
Correlations among covariates. The SUDS anticipatory anxiety variable was 
significantly associated with number of axis I diagnoses (r = .31, p < .01) and daily 
smoking rate (r = .25, p < .05). Gender was significantly associated with anticipatory 
anxiety – skin conductance reactivity (pre-challenge minute 9) (r = -.21, p < .05), with 
men manifesting greater levels of pre-challenge skin conductance reactivity than 
women. Finally, number of axis I diagnoses was significantly correlated with negative 
affectivity (r = .50, p < .01).  
Correlations between covariates and dependent variables. As expected, the 
SUDS anticipatory anxiety variable was significantly correlated with post-challenge 
SUDS anxiety ratings (r = .37, p < .01); and anticipatory anxiety – skin conductance 
reactivity was significantly associated with the skin conductance reactivity composite 
variable (average of challenge minutes 1-4) (r = .76, p < .01). Furthermore, gender was 
significantly associated with DSQ total score (r = .27, p < .01), with women reporting 
higher levels of panic-relevant responding than men. Number of axis I diagnoses was 
significantly correlated with post-challenge SUDS anxiety ratings (r = .32, p < .01).  
 Correlations between covariates and predictor variables. The SUDS 
anticipatory anxiety variable (r = .23, p < .05), number of axis I diagnoses (r = .45, p < 
.01), and negative affectivity (r = .62, p < .01) were each significantly associated with AS. 
 Correlations between predictor and dependent variables. Contrary to 
expectation, none of the predictor variables was significantly associated with any of the 
dependent variables. 
Hierarchical Regression Analyses3, 4, 5 
Table 4 presents a summary of the regression analyses.  
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 Self-reported anxiety, panic attack symptoms, and avoidance outcomes. In 
terms of post-challenge SUDS anxiety ratings, step one of the model accounted for a 
significant 17% of variance [F(5, 75) = 3.24, p = .01]. Pre-challenge SUDS anxiety 
ratings (β = .23, sr 2 = .05, p < .05) and number of axis I diagnoses (β = .30, sr 2 = .06, p 
< .05) were the only significant predictors. Contrary to hypothesis, steps two [F(2, 73) = 
.10, p = .90] and three [F(1, 72) = .88, p = .34] of the model did not account for 
significant portions of the model variance, and no significant predictors were noted at the 
level of main or interactive effects. 
 With regard to panic attack symptoms (DSQ  total score),6 the overall model, 
including steps one [F(5, 77) = 1.97, p = .09], two [F(2, 75) = 1.17, p = .31], and three 
[F(1, 74) = .23, p = .63], did not contribute any unique variance. Only gender was a 
significant predictor (β = .26, sr 2 = .07, p < .05). No other significant predictors were 
noted at the level of main or interactive effects. 
 In terms of behavioral avoidance of a future challenge, the overall model, 
including steps one [F(5, 74) = 1.80, p = .12], two [F(2, 72) = .72, p = .49], and three 
[F(1, 71) = .72, p = .39], did not contribute any unique variance. Both number of axis I 
diagnoses (β = -.37, sr2 = .08, p < .01) and negative affectivity (β = .27, sr2 = .05, p < .05) 
were significant predictors. No other significant predictors were noted at the level of main 
or interactive effects. 
 Physiological outcomes.7 In terms of skin conductance reactivity, step one of 
the model accounted for a significant 73% of variance [F(5, 69) = 37.79, p < .001].  Only 
pre-challenge skin conductance (recorded at minute 9 of pre-challenge baseline) was 
significantly predictive of skin conductance reactivity during the challenge (β = .84, sr 2 = 
.70, p < .001). No other significant predictors were noted at the level of main or 
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interactive effects, and neither steps two [F(2, 67) = .22, p = .80] nor three [F(1, 66) = 
.19, p = .66] accounted for significant portions of variance. 
Post Hoc Tests: Introduction 
 Due to the lack of empirical support for the hypotheses, a series of theoretically-
driven post hoc tests were completed. As with any post hoc exploration, caution is 
needed to interpret the findings. It is perhaps most prudent to utilize these additional 
analyses as a theory-generating tactic for future work focused on panic vulnerability 
processes among daily smokers; this type of information therefore should not be viewed 
as offering a ‗definitive conclusion.‘ 
Post Hoc Tests: First Series 
Post hoc tests were conducted, using the same models as described in the a 
priori Hypothesis Testing section, to examine the main and interactive relations between 
AS and withdrawal group status (Nicotine Deprivation vs. Non-Nicotine Deprivation; 
dichotomous variable) in relation to SUDS anxiety ratings during the challenge 
procedure (minutes 1-3 of the challenge). Repeated measures analysis of variance 
(ANOVA) procedures were conducted, as the dependent variable consists of a measure 
administered over 3 consecutive one-minute intervals (Tabachnick & Fidell, 2007). The 
partial eta squared (η2) coefficients were used as estimates of effect size (Tabachnick & 
Fidell, 2007). In the a priori tests, the SUDS dependent variable was recorded during the 
first minute post-challenge, as this has been the standard method of indexing panic-
relevant responding in the laboratory (Zvolensky et al., 1998).  
Consistent with the a priori tests, predictor variables were: (1) anticipatory anxiety 
(baseline SUDS rating, recorded at minute 9 of pre-challenge baseline), gender, number 
of axis I diagnoses, negative affectivity, and average daily smoking rate; (2) mean-
centered main effect for AS (ASI total score) and withdrawal group status (Nicotine 
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Deprivation vs. Non-Nicotine Deprivation; dichotomous variable); and (3) the interaction 
term for AS (mean-centered) and withdrawal group status. Peri-challenge SUDS anxiety 
ratings were obtained by asking participants to complete a SUDS questionnaire at 
minutes one, two, and three during the challenge procedure. This approach allows for 
more accurate testing of participants‘ anxiety levels during the CO2 challenge procedure, 
as participants provided ratings in real time during the challenge.  
Primarily, it was hypothesized that the interaction of AS (mean-centered) and 
withdrawal group status would significantly predict peri-challenge SUDS anxiety ratings, 
above and beyond the variance accounted for by the covariates and main effect terms. 
Specifically, it was expected that those individuals reporting higher levels of AS and 
randomly stratified to the Nicotine Deprivation Group would demonstrate the greatest 
level of anxious responding during the CO2 challenge procedure.  Secondarily, follow-up 
univariate ANOVA tests were planned, if a significant interactive effect was determined 
in the repeated measures ANOVA test, so as to isolate the time-points of the AS by 
withdrawal group status interactions. Here, it was hypothesized that the AS (mean-
centered) by withdrawal group status interactive effect would significantly predict anxious 
responding during minutes one and two of the challenge; these effects were not 
expected for minute three of the challenge. That is, it was expected that individuals with 
higher levels of AS and randomly stratified to the Nicotine Deprivation group would 
exhibit the highest levels of anxiety at the first two minutes of the challenge procedure. 
This interactive effect was not expected for challenge minute 3 because habituation was 
expected to occur beyond the second minute of the challenge (Beck, Shipherd, & Zebb, 
1997). The follow-up analyses would follow a model (covariates, main effects, interactive 
term) identical to that for the repeated measures ANOVA. A Bonferonni correction (.05/2 
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= .025) would be applied to the follow-up analyses to control for family-wise error rate 
(Tabachnick & Fidell, 2007). 
 Repeated measures ANOVA.   A 2 (withdrawal group status: Nicotine 
Deprivation vs. Non-Nicotine Deprivation) x 3 (SUDS assessment: minutes 1-3) 
repeated measures ANOVA was conducted, and the between-subjects effects were 
evaluated in terms of the predictive validity of each of the covariates, main effects, and 
interaction term (AS x withdrawal group status) on the SUDS within-subjects variable. 
Please see Figure 3 for a depiction of SUDS ratings over time by group. Please see 
Table 5 for a summary of results. 
 According to Mauchly‘s Test for sphericity, the sphericity assumption was 
violated [Mauchly‘s W = .88, Approximate Χ2 = 7.85, p = .02]. Therefore, the Huynh-Feldt 
statistic, a significance test adjusted for violation of the sphericity assumption 
(Tabachnick & Fidell, 2007), was used to interpret the test of within-subjects effects 
[F(2.00, 132.00) = 3.69, p < .05, partial η2 = .05].  In terms of between-subjects effects, 
pre-challenge SUDS anxiety ratings (minute 9 of pre-challenge baseline) were significant 
predictors of peri-challenge SUDS anxiety ratings [F(1, 66) = 4.46, p < .05, partial η2 = 
.06]. No other covariates were significant predictors.  Furthermore, the main effect of AS 
[F(1, 66) = 4.69, p < .05, partial η2 = .32] was a significant predictor of peri-challenge 
SUDS anxiety ratings; while the main effect of withdrawal group status was not a 
significant predictor. Finally, the interactive effect of AS by withdrawal group status was 
significantly incrementally predictive of peri-challenge SUDS anxiety ratings [F(1, 66) = 
5.53, p < .05, partial η2 = .07]. 
 Follow-up analyses. Two univariate ANOVAs were then performed to examine 
the time points at which significant AS by withdrawal group interactive effects were 
noted. Please see Table 5 for a summary of results. In terms of Challenge Minute 1 – 
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SUDS anxiety ratings, anticipatory anxiety (SUDS anxiety ratings, minute 9 of pre-
challenge baseline) [F(1, 70) = 8.08, p = .006, partial η2 = .10] and average daily 
smoking rate [F(1, 70) = 4.03, p = .04, partial η2 = .05] were the only significant covariate 
predictors.  
At the level of main effects, AS was a significant predictor [F(1, 70) = 5.20, p = 
.02, partial η2 = .06] of Challenge Minute 1 – SUDS anxiety ratings; withdrawal group 
status was not a significant predictor. As predicted, a significant AS by withdrawal group 
interactive effect was noted [F(1, 70) = 5.70, p = .02, partial η2 = .07].  
 With regard to Challenge Minute 2 – SUDS anxiety ratings, none of the 
covariates were significant predictors. Neither of the main effect variables yielded 
significant predictive effects. However, as expected, a significant AS by withdrawal 
group interactive effect was noted [F(1, 78) = 8.92, p = .004, partial η2 = .11].   
 It might be noted that, as hypothesized, the AS by withdrawal group interaction 
did not significantly predict Challenge Minute 3 – SUDS anxiety. Negative affectivity [F(1, 
66) = 5.07, p = .02, partial η2 = .07] and AS [F(1, 66) = 4.90, p = .03, partial η2 =.06] were 
the only significant predictors.  
Mapping the forms of the significant interactions.  Based on the 
recommendations of Cohen and Cohen (1983), the forms of the significant interactions 
were examined by inserting specific values for each predictor variable into the equations 
associated with the described analysis (one standard deviation above and below the 
mean for AS). As can be seen in Figure 4, the forms of the significant interactions varied 
between Challenge Minute 1 and Minute 2. The effects at Minute 2 were consistent with 
hypothesis, while the effects at Minute 1 were inconsistent with hypothesis.  
At Challenge Minute 1, the highest levels of SUDS anxiety ratings were 
evidenced first by individuals in the Non-Nicotine Deprivation Group reporting high levels 
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of AS (n = 6); second by individuals in the Nicotine Deprivation Group reporting high 
levels of AS (n = 7); third by individuals in the Non-Nicotine Deprivation Group reporting 
low levels of AS (n = 11); and fourth by individuals in the Nicotine Deprivation Group 
reporting low levels of AS (n = 4). Therefore, the effects at Minute 1 were not consistent 
with hypotheses.  
At Challenge Minute 2, the highest levels of SUDS anxiety ratings were reported 
first by individuals in the Nicotine Deprivation Group reporting high levels of AS (n = 6); 
second by individuals in the Non-Nicotine Deprivation Group reporting high levels of AS 
(n = 6); third by individuals in the Non-Nicotine Deprivation Group reporting low levels of 
AS (n = 9); and fourth by individuals in the Nicotine Deprivation Group reporting low 
levels of AS (n = 3). The effects at Minute 2 were consistent with hypotheses. 
Post Hoc Tests: Second Series 
 Due to the inconsistent findings for the AS by withdrawal group status interactive 
effects at SUDS – Minute 1 and SUDS – Minute 2 post-challenge, nicotine withdrawal 
symptoms (MWS total score) were examined (by withdrawal group status) at two distinct 
time-points during the challenge procedure (minute 9 of pre-challenge baseline; post-
challenge) to determine whether group differences in self-reported nicotine withdrawal 
symptoms were indeed maintained over time. As per the a priori group comparisons and 
manipulation checks, the groups significantly differed at pre-challenge (please see Table 
1), and therefore, this time-point was not included in these post hoc tests. It was 
hypothesized that the Nicotine Deprivation group, as compared to the Non-Nicotine 
Deprivation group, maintained significantly higher levels of self-reported nicotine 
withdrawal symptoms over the course of the challenge procedure. 
A repeated measures ANOVA procedure was conducted, as the dependent 
variable consists of a measure administered over 2 time-points, with an (approximate) 8-
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10 minute interval between administrations (Tabachnick & Fidell, 2007). The partial eta 
squared (η2) coefficients were used as estimates of effect size (Tabachnick & Fidell, 
2007). Specifically, a 2 (withdrawal group status: Nicotine Deprivation vs. Non-Nicotine 
Deprivation) x 2 (MWS assessment: minute 9 of pre-challenge baseline, post-challenge) 
repeated measures ANOVA was conducted, and the between-subjects effects were 
evaluated in terms of the MWS within-subjects variable. Please see Figure 5 for a 
depiction of MWS ratings over time by group.  
Since the within-subjects variable (MWS total score at 2 time-points) has only 
two levels, the issue of sphericity is not applicable (Tabachnick & Fidell, 2007). In terms 
of between-subjects effects, withdrawal group status did not significantly predict MWS 
symptoms over time [F(1, 77) = .57, p = .45], indicating that groups did not significantly 
differ in terms of nicotine withdrawal symptoms beyond the first pre-challenge baseline 
time-point.  
Discussion 
 The overarching aim of the present investigation was to delineate empirical 
associations and interactive effects between AS, a cognitive risk factor for PD, and acute 
(12-hour) nicotine withdrawal in order to better understand the etiology of panic 
vulnerability processes. Linking theory and research on panic vulnerability and smoking 
processes, this study provided a novel test of the interplay between AS and nicotine 
withdrawal (group status) -- using an experimental CO2-enriched air laboratory paradigm 
-- in predicting anxious, panic-relevant responding as indexed by: (1) level of post-
challenge anxiety focused on bodily sensations and intensity of panic attack symptoms; 
(2) skin conductance reactivity; and (3) level of behavioral avoidance of a future 
challenge.  Post hoc tests were also conducted to examine the interactive effects of AS 
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and nicotine withdrawal group status on peri-challenge anxiety ratings (minutes 1-3 of 
the challenge). 
Interactive Effects 
A priori tests.  Contrary to hypothesis, the interactive effect of AS by nicotine 
withdrawal (group status) did not significantly predict post-challenge anxiety (SUDS) 
ratings, intensity of panic attack symptoms, skin conductance reactivity, or level of 
avoidance of a future challenge. Furthermore, there was no association with this 
interactive variable and any other physiological factor, including heart rate reactivity or 
respiration rate. This pattern of findings was not attributable to the definition of ‗nicotine 
withdrawal,‘ since results were consistent even when withdrawal was defined 
continuously using all participants‘ pre-challenge MWS total scores (please see Footnote 
5). Furthermore, this pattern of findings was not attributable to the definition of panic 
attack intensity (DSQ), since the results were consistent when either of the DSQ 
subscales (Physical Concerns or Cognitive Concerns) were examined as dependent 
variables and when the DSQ was scored, according to DSM-IV criteria, to index panic 
attacks (yes/no; dichotomously) or number of panic attack symptoms continuously 
(please see Footnote 6). Therefore, AS and nicotine withdrawal did not demonstrate a 
synergistic effect in terms of the a priori defined aspects of panic vulnerability (self-report 
or physiological). It is unlikely that these findings are attributable to statistical power, 
since the sample consisted of 90 individuals; a sample size consistent with the planned 
power analysis, which was based on past work (Abrams et al., in press; Zvolensky, 
Feldner, Leen-Feldner et al., 2005). Furthermore, no trends toward statistical 
significance were noted for any of the interactive effects, underscoring the lack of an 
apparent interactive effect in terms of these dependent variables. The null findings 
relevant to the a priori hypotheses are broadly consistent with a related study by Piper 
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and Curtin (2006), which found that nicotine deprivation did not affect emotional 
response intensity and emotion regulation success in response to experimental 
manipulation of affect (via presentation of a series of neutral and negatively-valenced 
photographs) among 48 nicotine dependent smokers, assigned to either continued 
smoking or 24-hour nicotine deprivation. Yet, several methodological and sample 
limitations may have confounded these findings, and these potential caveats are 
discussed below (please see Methodological Limitations and Sample Limitations 
sections below). 
Post hoc tests.  A series of post hoc tests were conducted to test whether AS 
moderated the effect of nicotine withdrawal (group status) and peri-challenge 
responding, as indexed by SUDS anxiety ratings taken at minutes 1-3 during the 
challenge. First, the interactive effect of AS by withdrawal group significantly predicted 
Challenge Minute 1 – SUDS anxiety ratings, with a small effect size (η2 = .07). However, 
the forms of the significant effects were inconsistent with hypotheses. At minute 1 of the 
challenge, individuals high in AS and in the Non-Nicotine Deprivation group reported the 
highest levels of anxiety, followed by the high AS individuals in the Nicotine Deprivation 
group. Second, as expected, AS moderated the association between nicotine withdrawal 
(group status) and Challenge Minute 2 - SUDS anxiety ratings, with a small – moderate 
effect size (η2 = .11). Here, the forms of the interactions were consistent with hypotheses 
and individuals in the Nicotine Deprivation group with high levels of AS indexed the 
highest levels of anxious responding, followed by high AS individuals in the Non-Nicotine 
Deprivation group. Third, as predicted, no significant interactive effects were noted at the 
third minute of the challenge, possibly due to habituation effects (Beck et al., 1997).   
 These findings are novel in at least three significant ways. First, no studies to 
date have attempted to experimentally manipulate nicotine withdrawal and to examine its 
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interactive effect with AS in predicting panic responding.  Second, this was the first study 
to date to index nicotine withdrawal symptoms during the course of a challenge 
procedure to assess changes in self-reported withdrawal symptoms over time by 
nicotine deprivation group. Third, this was the first study to date in this literature to also 
index anxiety ratings during the challenge, in addition to the more traditional post-
challenge ratings, and to use peri-challenge anxiety ratings as dependent variables in a 
test of interactive effects.  
The results may be informed by several theoretical accounts of smoking-anxiety 
interplay (Zvolensky & Bernstein, 2005). First, the significant interaction of AS by Non-
Nicotine Deprivation (smoking as usual) in predicting anxious responding during minute 
1 of the challenge is broadly consistent with past work using cross-sectional approaches 
that has indexed similar interactive effects (McLeish et al., 2007). It also is consistent 
with laboratory work that has documented higher levels of challenge-relevant panic 
reactivity among smokers (Zvolensky, Leen-Feldner et al., 2004). Therefore, it may 
suggest that smoking as usual (and immediately pre-challenge) may uniquely interact 
with AS to predict an escalation of anxiety symptoms in the context of increased 
physiological arousal.  
Theoretically, this type of account may be attributed to at least three factors, 
which are worthy of further empirical exploration. First, it is possible that recent smoking 
in a group of daily smokers (Non-Nicotine Deprivation group) may cause increases in 
acute shortness of breath or perceived shortness of breath that may be attenuated by 
even 12 hours of smoking abstinence (Nicotine Deprivation group). These types of 
respiratory difficulties may be exacerbated by wearing a C-Pap mask, and this effect 
therefore might have contributed to the higher levels of anxiety at pre-challenge, 
challenge minute 1, and challenge minute 3 reported by those in the Non-Nicotine 
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Deprivation group. This possibility is informed by the work of Abrams et al. (in press), 
which found that smokers, as compared to non-smokers, manifested significantly greater 
trait levels of suffocation fear. Future work might index these potential respiratory effects 
using more sensitive psychophysiological equipment than that used in the present study 
as well as specialized self-report measures to index respiratory problems. Second, 
although there is a dearth of empirical evidence relevant to the acute biological effects of 
smoking, it is possible that a variety of neurobiological effects elicited by recent nicotine 
use might be linked to greater anxious responding to the induction of physiological 
arousal via the challenge paradigm. For example, smoking behavior has been 
associated with acute, mild-moderate increases in the neurotransmitter dopamine and 
elevated dopamine  levels have been linked to increased anxiety-relevant symptoms, 
such as hyperarousal (Barrett, Boileau, Okker, Pihl, & Dagher, 2004; Brody et al., 2004; 
Hughes, 2007b; Takahashi et al., 2007). Therefore, from a psychobiological perspective, 
it is possible that individuals in the Non-Nicotine Deprivation group reported higher 
anxiety symptoms as a result of acute surges in dopamine, a result of recent nicotine 
administration (smoking prior to the challenge). Future research in this area is needed to 
further investigate the psychobiological effects of smoking, using positron emission 
topography (PET) scans, magnetic resonance imaging (MRI), and/or computerized axial 
tomography (CT) scans, for example; and how such effects might interplay with cognitive 
or affective factors in eliciting anxiety symptoms. Finally, since the onset of nicotine 
withdrawal symptoms may occur within minutes of smoking (Jarvik et al., 2000; Schuh & 
Stitzer, 1995), it is possible that (relatively low) nicotine withdrawal symptoms in both 
groups were partially accounting for the anxiety effects. This theoretical possibility is 
discussed further below (please see p. 58).  
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Second, the significant moderating effect of AS in terms of the association 
between the Nicotine Deprivation group and anxious responding at Challenge – Minute 2 
is consonant with a priori postulation and past work documenting the effect of nicotine 
withdrawal symptoms in eliciting panic responsivity among smokers (Zvolensky & 
Bernstein, 2005). Therefore, it may be that smoking as usual (and just minutes before 
the challenge) is just as potent as nicotine withdrawal symptoms in eliciting panic-
relevant anxiety symptoms but at differing stages (minutes 1 and 2, respectively) of the 
onset of panic-relevant sensations. Thus, the mechanism by which smoking and panic-
spectrum psychopathology are linked may be more complex than initially anticipated, 
and future work is necessary to replicate and extend the current findings.  
However, it should be noted that, as suggested by the second series of post hoc 
tests, nicotine withdrawal symptoms increased for individuals in the Non-Nicotine 
Deprivation group over the course of the challenge protocol. Although the Nicotine 
Deprivation group, as compared to the Non-Nicotine Deprivation group, reported 
significantly higher levels of nicotine withdrawal symptoms at the first pre-challenge time-
point, these significant group differences diminished by minute 9 of the pre-challenge 
baseline period and were not evident at post-challenge either (please see Figure 5). In 
addition, the Non-Nicotine Deprivation group evidenced a consistent increase in 
withdrawal symptoms over the three time-points, while the Nicotine Deprivation group 
indexed a drop in nicotine withdrawal symptoms at minute 9 of pre-challenge baseline, 
perhaps due to habituation to anticipatory anxiety (Beck et al., 1997), and another 
increase in symptoms at post-challenge, possibly related to increased anxiety during the 
challenge. Furthermore, it might be noted that the findings may be due to flaws inherent 
in the manipulation of nicotine withdrawal (please see Methodological Limitations 
section), which may have yielded inadvertently erroneous effects.    
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Third, as depicted in Figure 4, patterns of anxiety ratings between groups (over 
the course of the challenge) are worthy of note. Differences between high AS and low 
AS individuals – regardless of group status – are apparent at pre- and post-challenge 
time-points. High AS individuals reported significantly higher levels of anxiety ratings 
than the low AS individuals, regardless of group. That is, high AS individuals in the Non-
Nicotine Deprivation and Nicotine Deprivation groups reported relatively similar levels of 
SUDS anxiety ratings at pre- and post-challenge. At Challenge Minute 1, high AS 
individuals in the Non-Nicotine Deprivation group (M = 83.33, SD = 20.41) reported the 
highest levels of anxiety ratings, but the mean difference in anxiety ratings with the high 
AS – Nicotine Deprivation group (M = 78.57, SD = 17.25) is small. At Challenge Minute 
2, the effect is reversed with high AS individuals in the Nicotine Deprivation group (M = 
83.33, SD = 12.90) reporting the highest levels of anxiety; but again the difference with 
the high AS - Non-Nicotine Deprivation group (M = 75.00, SD = 31.62) is rather small. At 
Challenge Minute 3, the high AS individuals in the Non-Nicotine Deprivation group 
reported the highest anxiety ratings (M = 87.50, SD = 20.91), while the high AS 
individuals in the Nicotine Deprivation group (M = 66.66, SD = 25.81) reported the same 
levels of anxiety as the low AS individuals in the Non-Nicotine Deprivation group (M = 
66.66, SD = 21.65). At post-challenge, high AS individuals in either group reported 
approximately equivalent anxiety ratings, which suggests that anticipatory anxiety and 
recovery processes might be the same for all high AS smokers following physiological 
evocation, regardless of nicotine deprivation schedules. Yet, due to the preliminary 
nature of this study and the small sample size of high AS individuals (n = 13; high AS 
defined as one standard deviation above the mean) in the current study, replication and 
extension of this work is necessary prior to further theoretical extrapolation. 
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Furthermore, low AS individuals reported significantly lower levels of anxiety 
ratings than the high AS individuals from pre- to post-challenge, regardless of group. 
Interestingly, at Challenge Minute 1, low AS individuals in the Non-Nicotine Deprivation 
group (M = 58.00, SD = 31.64) reported higher levels of anxiety than individuals in the 
low AS – Nicotine Deprivation group (M = 41.66, SD = 28.86). These group differences 
among low AS individuals continued through minutes 2 and 3 of the challenge. This may 
suggest that, for low AS individuals, recent smoking (smoking as usual) may be more 
associated with panic-relevant anxiety in response to physiological evocation than 12-
hour nicotine deprivation. At pre- and post-challenge, low AS individuals in both groups 
reported relatively equivalent anxiety ratings (consistent with the pattern of findings for 
high AS individuals, discussed above), suggesting anticipatory anxiety and recovery 
processes might be similar for all low AS smokers following physiological evocation, 
regardless of nicotine deprivation schedules. However, due to the preliminary nature of 
this study and the very few individuals upon which this is based (low AS individuals in 
both groups: n = 15), the results should be interpreted with caution and further 
theoretical extrapolation should be postponed until replication of the current work is 
completed. 
Main Effects 
Neither AS nor withdrawal group status were significantly incrementally predictive 
of any of the (a priori) dependent measures, including post-challenge anxiety (SUDS) 
ratings, intensity of panic attack symptoms, skin conductance reactivity, or level of 
avoidance of a future challenge. AS and nicotine withdrawal (group status) also did not 
demonstrate significant incremental associations with other physiological variables 
(please see Footnote 7) or zero-order correlations with these dependent variables. Post 
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hoc tests revealed significant incremental main effects for AS in terms of SUDS anxiety 
ratings at minutes 1 and 3 of the challenge. 
AS.  Contrary to extensive empirical work citing significant associations between 
AS and panic-relevant responding, using biological challenge approaches (Zinbarg et al., 
2001) and longitudinal designs (Schmidt et al., 1997, 1999), the results of this study 
indicated significant relations between AS and fear responsivity only at minutes 1 and 3 
of the challenge. This may be due to at least two key factors. First, the current study did 
not sample specifically for high AS individuals, and therefore, the higher-end variability in 
AS was attenuated. Specifically, only 13 individuals reported levels of AS one standard 
deviation above the mean; and 15 individuals reported levels of AS one standard below 
the mean. This indicates that, as might be expected, most individuals reported moderate 
levels of AS (Reiss et al., 1986). However, the relatively normative levels of AS 
evidenced by the majority of the sample might have significantly limited the possibility of 
observing AS-anxiety effects.    
Second, to be consistent with the bulk of past work in this area, AS was 
measured continuously/dimensionally, using the total score yielded by the ASI. Recent 
latent structural research on AS has indicated that the construct may demonstrate a 
taxonic structure (e.g., Bernstein, Zvolensky, Norton et al, 2007), such that higher-end 
levels of AS – determined using taxometric methodologies – represent a more valid 
approach to examining risk for panic-relevant psychopathology (Bernstein & Zvolensky, 
2007). Recent work has evidenced that dimensional measures of the construct, such as 
the ASI total score used in the present investigation, reflect latent taxonic individual 
differences in the construct (Bernstein et al., 2007) that may be especially useful in 
models of affective vulnerability. The AS taxon, as compared to the more traditional, 
dimensional measures of AS, has been associated with higher levels of predictive 
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validity in terms of panic-relevant outcomes (Bernstein et al., 2007). In the present 
investigation, AS was evaluated dimensionally; taxometric methods were not employed 
due to design limitations (i.e., small sample size).  Future investigations that are 
methodologically (e.g., large sample size) and statistically designed to incorporate 
taxonic and dimensional structures could further evaluate and compare the relations 
between AS – indexed both as the AS taxon and the AS dimensional variable -- and 
nicotine withdrawal and panic responding. 
Nicotine withdrawal. Nicotine withdrawal group status was not incrementally 
predictive of any of the studied dependent variables, and no zero-order associations 
were noted, either. Notably, when the analyses were conducted using a continuous 
index of nicotine withdrawal (MWS – total score), then nicotine withdrawal symptoms 
were a significant predictor of panic attack symptoms during the challenge (please see 
Footnote 5). This finding is consistent with past work that has shown incremental 
associations between nicotine withdrawal symptoms and panic symptoms (Zvolensky, 
Feldner, Leen-Feldner et al., 2005). 
Given that scores on the MWS may range from 0 – 21, the nicotine withdrawal 
symptom severity scores endorsed by the Nicotine Deprivation group (M = 5.81, SD = 
4.32) were rather low even at the first pre-challenge assessment, with only 7 individuals 
reporting scores one standard deviation above the mean and only 1 participant 
endorsing a score above 15. This data is highly significant in terms of offering a potential 
explanation for the null a priori hypotheses, and it underscores the importance of 
considering the possible flaws in the manipulation of nicotine withdrawal (discussed 
below in the Methodological Limitations section).  
Finally, given the differential patterns of nicotine withdrawal symptoms reported 
by the Nicotine Deprivation and Non-Nicotine Deprivation groups at the first pre-
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challenge time-point, minute 9 of the pre-challenge baseline period, and post-challenge 
(please see Interactive Effects section above), changes in self-reports of nicotine 
withdrawal symptoms may have unexpectedly confounded the results. Since the Non-
Nicotine Deprivation and Nicotine Deprivation groups were reporting relatively similar 
levels of nicotine withdrawal symptoms by minute 9 of the pre-challenge baseline period, 
the theoretical premise for random assignment of participants to withdrawal group 
(Nicotine Deprivation vs. Non-Nicotine Deprivation) was null prior to the administration of 
the CO2-enriched air. This effect may due to (1) habituation or anxiety elicited by the 
challenge (as discussed in the Interactive Effects section above) or (2) flaws in the 
experimental manipulation of nicotine ‗withdrawal‘ (please see Methodological 
Limitations section below). 
Other Noteworthy Observations 
Anticipatory anxiety. Anticipatory anxiety (pre-challenge SUDS ratings) was 
significantly associated with post-challenge SUDS ratings and Challenge – Minute 1 
SUDS ratings but not with SUDS ratings at minutes 2 or 3 of the challenge. Thus, pre-
challenge anxiety appears to be the most relevant for explaining early (minute 1) and 
later (post-challenge) aspects of anxious responding to bodily perturbation. 
Pre-challenge skin conductance was a significant predictor of skin conductance 
reactivity, accounting for 73% of variance. This finding is consistent with past work, 
which has found that skin conductance levels pre-challenge account for high levels of 
variance in skin conductance reactivity during the challenge (e.g., Stewart & Pihl, 1994).  
Gender. Gender was the only significant predictor of panic attack symptoms (β = 
.26, sr2 = .07, p < .05), with women reporting significantly higher levels of panic attack 
symptoms during the challenge than men. This gender effect is consistent with (1) the 
higher prevalence rates of panic disorder in women than men (APA, 2000), and (2) 
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laboratory studies that have documented higher rates of challenge-relevant panic 
responsivity among women as compared to men (Kelly, Forsyth, & Karekla, 2006).  
Number of axis I diagnoses. The number of axis I diagnoses was significantly 
predictive of post-challenge anxiety as well as behavioral avoidance of a future 
challenge. Although the withdrawal groups did not differ in terms of number of axis I 
diagnoses, it seems that the presence of more complex psychopathology (indexed by a 
higher rate of psychiatric comorbidity) was a significant factor in predicting anxious 
challenge responding among daily smokers. Furthermore, at the zero-order level, 
number of axis I diagnoses was significantly correlated with anticipatory anxiety (SUDS 
ratings), negative affectivity, AS, and post-challenge anxiety (SUDS ratings). This finding 
is consistent with past work, which has documented that clinical samples generally 
respond more anxiously to panic evocation paradigms than nonclinical samples 
(Zvolensky & Eifert, 2000). This study also replicates past work that has examined 
panic-relevant responding among clinical samples of smokers and found that smokers 
with current axis I psychopathology are more apt to respond anxiously to affect 
evocation paradigms than smokers without current axis I psychopathology (Feldner, 
Vujanovic, Gibson, & Zvolensky, in press; Zvolensky, Leen-Feldner et al., 2004).  It may 
be important for future work to replicate and extend these findings across clinical 
samples to document panic-relevant etiology and maintenance processes among other 
types of psychopathology.   
 Negative affectivity.  Negative affectivity was a significant predictor of post-
challenge avoidance and anxiety ratings at minute 3 of the challenge. These findings are 
broadly consistent with past work that indicates negative affectivity is related to anxiety 
and distress to bodily sensations (Zvolensky, Feldner, Eifert, & Stewart, 2001). At the 
zero-order level, negative affectivity was significantly associated with number of axis I 
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diagnoses and AS. Again, this finding is in line with work highlighting a relation between 
a temperamental tendency to experience negative affect and a variety of psychiatric 
conditions (Watson, 2005). 
 Daily smoking rate.  Daily smoking rate was significantly predictive of only 
anxiety ratings at minute 1 of the challenge. Therefore, in terms of anxiety at minute 1 of 
the challenge, both daily smoking rate and the interaction of AS by Non-Nicotine 
Deprivation group (smoking as usual) predicted higher levels of anxiety. Theoretically, 
daily smoking rate and smoking as usual may be particularly predictive of anxious 
responding during the onset of panic-relevant physiological arousal. This conclusion is 
consistent with past work, which has found that daily smoking rate is significantly 
associated with panic-relevant psychopathology in community samples (Hayward et al., 
1989, Valentiner et al., 2004) as well as panic-relevant responding in laboratory studies 
(Zvolensky, Leen-Feldner et al., 2004). In addition, smokers, as compared to 
nonsmokers, have been found to evidence higher rates of anxious responding to 
biological challenge paradigms (e.g., Abrams et al., in press).  At the zero-order level, 
daily smoking rate was significantly correlated with anticipatory anxiety (SUDS ratings), 
which also suggests that daily smoking rate may contribute to higher levels of (baseline) 
anxiety. Collectively, these findings add to past research by providing laboratory 
evidence of a smoking-anxiety linkage to somatic perturbation. 
Group differences. Although participants were randomly assigned to withdrawal 
group (Nicotine Deprivation vs. Non-Nicotine Deprivation), two key between-group 
differences were nonetheless evident. Specifically, the Non-Nicotine Deprivation group 
was significantly older and reported (daily) smoking for a greater number of years than 
the Nicotine Deprivation group. Therefore, it is possible that age and longer smoking 
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history may have contributed to the higher levels of anxiety reported by the Non-Nicotine 
Deprivation group at pre-challenge and minutes 1 and 3 of the challenge. 
Methodological Limitations 
 Since many of the findings yielded by the current study are inconsistent with 
theoretical and empirical precedent, it is important to interpret the findings as preliminary 
and to contextualize the results within several methodological limitations which may 
have confounded the effects. First, the manipulation of nicotine withdrawal in the current 
study was standardized to a 12-hour overnight nicotine deprivation period. Although this 
manipulation was consistent with theoretical and empirical precedent (Hughes et al., 
1990), it is possible that the overnight deprivation may have attenuated the nicotine 
withdrawal effects. Since some theoretical models of smoking posit that nicotine 
withdrawal is classically conditioned (Gilbert, 1995), it is possible that the absence of 
behavioral or environmental cues in the overnight deprivation schedule may have 
inadvertently decreased the effect of nicotine withdrawal symptoms for smokers in the 
Nicotine Deprivation group.   
 Second, all participants were instructed to not use any form of nicotine 
replacement therapy during their involvement in the study, and this information was only 
verbally verified at both study appointments. Therefore, it is possible that some 
participants in either the Nicotine Deprivation or Non-Nicotine Deprivation groups 
nevertheless elected to use nicotine replacement products, thus potentially confounding 
their self-reported nicotine withdrawal or affective symptoms as well as their anxious 
responding to the challenge (e.g., Morissette, Palfai, Gulliver, Spiegel, & Barlow, 2005; 
Tiffany, Cox, & Elash, 2000). For instance, past work has shown that smokers using 
transdermal nicotine patches, as compared to smokers using placebo patches, reported 
lower self-reported smoking urges and lower levels of negative affectivity (Morissette et 
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al., 2005; Tiffany et al., 2000). Due to the paucity of research examining the effects of 
nicotine replacement therapies on the cognitive-affective experiences of smokers, it is 
important for future work to more closely monitor and verify the use of nicotine 
replacement products in studies of nicotine withdrawal and anxiety. 
Third, the challenge paradigm was standardized so that audio-taped instructions 
(1) directed participants to complete questionnaires at specific times throughout the 
challenge and (2) signaled the onset and offset of the CO2-enriched air administration. 
As shown in Figure 3, both the Nicotine Deprivation and Non-Nicotine Deprivation 
groups evidenced a drop in SUDS anxiety ratings at post-challenge. Since three of the 
dependent variables were indexed via post-challenge measures (SUDS, DSQ, 
Behavioral Avoidance Measure), it is possible that the announcement of the offset of the 
CO2 administration was related to collective relief (i.e., lower levels of anxiety) among 
participants, which confounded the findings relevant to these measures. Thus, future 
work might manipulate the challenge protocol such that participants are asked to index 
final panic-relevant ratings either (1) prior to the offset of the CO2 administration or (2) 
without an audio-taped offset prompt.  
Fourth, although there is evidence of the potency of the current challenge 
administration in eliciting increases in self-reported anxiety ratings and physiological 
responding (please see Table 2), the challenge is still a departure from the experience of 
real-world anxiety or panic symptoms.  The CO2-enriched air experimental paradigms 
are reliably utilized to elicit panic-relevant symptoms (Zvolensky & Eifert, 2000) and 
provide a controlled setting in which to study panic-related psychopathology without the 
biases relevant to retrospective self-report data. However, the limitations inherent to the 
laboratory setting (e.g., psychophysiological and audio-visual monitoring, breathing via 
mask, audio-taped instructions, questionnaire completion) should be considered in 
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interpreting the current data. Future work might use ecological momentary recording 
devices to facilitate recording of panic-relevant sensations, smoking behavior, and 
nicotine withdrawal symptoms in real time to monitor individuals‘ symptoms across a 
variety of settings and times. This type of methodology would increase generalizability 
and ecological validity, while reducing the ‗artificiality‘ of effects generated by a 
laboratory setting. 
Fifth, although the challenge protocol was standardized via the use of audio-
taped instructions, several interpersonal factors may have affected the results. Primarily, 
it should be noted that, due to staffing issues, the Principal Investigator met with all 
participants across both study sessions. By virtue of this design, participants‘ familiarity 
and rapport with the Principal Investigator, established during the first session, might 
have contributed to (1) increases in overall comfort level during the second 
(experimental) session, (2) increases in social desirability biases in reporting anxiety or 
nicotine withdrawal symptoms at the second session, and (3) greater levels of perceived 
safety during the challenge procedure, which might have led to lower reports of anxiety 
or discomfort during the challenge. Furthermore, the study design did not provide an 
experimenter script to standardize the interactions between the experimenter and 
participant at the second session, prior to the audio-taped segment. Therefore, the 
experimenter interacted with participants in an unstandardized manner for approximately 
10 minutes prior to the standardized portion of the session in order to conduct CO 
analysis of breath sampling, administer pre-challenge questionnaires, and fasten 
physiological electrodes. Past work has shown that unstandardized interpersonal 
interaction may inadvertently serve to develop or support rapport, which may confound 
the findings of challenge methodologies (Rassovsky & Kushner, 2003). Therefore, future 
work might control for these types of factors by employing different personnel to 
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administer interviews versus challenge protocols and by standardizing all experimenter-
participant interactions at the challenge appointment.  
 Finally, the one-item Post-Challenge Avoidance Measure employed in the current 
study indexed participants‘ willingness to participate in another challenge paradigm 
within 2 weeks of the second session date. Interpretations of findings related to this 
measure should be interpreted with caution for at least three significant reasons. The 
lack of immediacy inherent to the item wording (i.e., 2-week time-frame) might have 
confounded the results by not indexing immediate fear-related avoidance in real time. 
Participants‘ reports of their desire to participate in a future challenge may not be fully in 
line with their actual behavior, such that participants may report that they would be 
willing to return but may not actually intend or desire to follow through (and vice versa). It 
also is possible that this measure of avoidance taps boredom, frustration, social 
desirability, desire for monetary reward, or related factors rather than ‗pure‘ fear-driven 
avoidance. Thus, future work should attempt to solidify the current findings through a 
more rigorous methodology. For example, future work intended to index panic-related 
avoidance might incorporate a second challenge minutes following the first challenge to 
more accurately assess willingness to engage in another challenge; and changes in 
affective responsivity (habituation or lack thereof) could be assessed, as well. 
Sample Limitations 
 Although broad-based community recruitment strategies were utilized, the 
sample has several limitations worthy of note. First, participants were relatively 
homogeneous in terms of race/ethnicity, as 93.3% of the sample identified as 
white/Caucasian. To increase the generalizability of the current findings, future work may 
wish to sample from more diverse populations. Second, individuals comprising the 
current sample participated in the study for monetary reward and were not necessarily 
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interested in quitting smoking at the time of entry into the study. To rule out possible self-
selection bias and to increase the ecological validity of the findings, it may be important 
for future work in this domain to utilize recruitment tactics other than those implemented 
in the current study (e.g., recruiting smokers with a desire to quit smoking). Not sampling 
smokers who were attempting smoking cessation may have contributed error to the 
study, as several motivational and expectancy processes relevant to AS and other 
pertinent affective processes (e.g., negative affectivity) may not have been relevant to 
the present sample, thus limiting generalizability (Leyro et al., in press; Zvolensky, 
Vujanovic et al., 2007). Third, participants in the current study endorsed relatively low 
levels of nicotine dependence (FTND total score: M = 3.40, SD = 1.93; FTND possible 
range: 0-8). Since higher levels of nicotine dependence have been associated with more 
intense nicotine withdrawal symptoms (Hughes, 2007a), it is possible that nicotine 
dependence attenuated the effects of withdrawal symptoms on anxious responding in 
the current study. It will be important for future work to specifically recruit more highly 
nicotine dependent smokers in order to better understand the role of nicotine 
dependence in the association between nicotine withdrawal, AS, and panic-relevant 
responding. Fourth, future work in this domain should recruit and enroll a gender-
matched sample in light of the current gender differences in self-reported panic attack 
symptoms (reported above) and past work documenting women‘s greater anxious 
responsivity (Kelly et al., 2006) to rule out any potential gender effects.  As the current 
sample was predominantly male (n = 55 of 90), it is possible that this factor may have 
inadvertently affected the results.  
Fifth, a high percentage of the current sample reported being regular marijuana 
and alcohol users; approximately 20% of the sample reported using marijuana more 
than once per day, and 54.4% of the sample met criteria for moderate alcohol problems. 
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Concurrent substance use was not conceptualized a priori as a potential confound to the 
current investigation. There is a relative dearth of literature examining the impact of 
regular marijuana or alcohol use on nicotine withdrawal symptoms or panic-relevant 
responding, and therefore, there is the potential that regular use of these substances 
may have affected either nicotine withdrawal symptoms, self-reported anxious 
responding to the challenge, or physiological responsivity to the challenge paradigm. On 
a related note, the presence of DSM-IV substance use disorders was not formally 
assessed in the present study. It is therefore possible that participants met criteria for 
other substance use disorders (e.g., opiate abuse), and that this type of substance use 
affected the current results. It may be important for future work in this line of inquiry to 
more rigorously assess substance use and to exclude individuals who use substances 
other than nicotine regularly in order to more conclusively delineate linkages between 
nicotine withdrawal and panic responding. 
Clinical Implications 
 There are at least three key clinical implications of the present work. The 
interaction of AS by nicotine deprivation as well as AS by non-nicotine deprivation 
(smoking as usual) in predicting anxiety symptoms during the challenge underscores the 
important association between AS and panic responsivity among smokers. Primarily 
therefore, the incorporation of AS reduction techniques (e.g., interoceptive exposure), 
corresponding cognitive-behavioral skills, and relevant psychoeducation into smoking 
cessation programs may yield very promising results (Zvolensky & Bernstein, 2005). By 
learning coping skills relevant to anxiety-relevant bodily sensations, higher AS smokers 
may be better able to quit smoking because they might develop the skills to substitute 
more adaptive emotion regulation skills for the (perceived) affect regulatory properties of 
smoking. Secondarily, PD prevention programs might be developed for high AS smokers 
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whereby AS reduction techniques (e.g., interoceptive exposure, cognitive-behavioral 
skills) are combined with standard smoking cessation techniques to prevent the 
development of PD among this high risk group (via decreasing AS and facilitating 
smoking cessation; Feldner, Zvolensky, Babson, Leen-Feldner, & Schmidt, in press). 
Third, as higher levels of AS have been linked to various types of psychological 
syndromes and conditions (e.g., posttraumatic stress disorder, chronic pain), advancing 
clinical science relevant to the AS – smoking association in the context of other clinical 
syndromes may be especially fruitful in terms of informing more specialized smoking 
cessation intervention programs and possibly developing various specialized prevention 
programs for high AS smokers (Feldner et al., 2008). 
Summary 
 The current investigation adds uniquely to the extant literature relevant to AS – 
smoking associations. This study presented an innovative effort to experimentally 
manipulate nicotine withdrawal, to measure anxiety ratings peri-challenge, and to test 
the interactive effects of AS by nicotine withdrawal in predicting anxious responding to a 
CO2-enriched air laboratory paradigm. At Challenge – Minute 1, AS moderated the 
association between Non-Nicotine Deprivation (smoking as usual) and anxious 
responding. At Challenge – Minute 2, AS moderated the association between Nicotine 
Deprivation and anxious responding. Overall, this study offers a significant stepping 
stone for future translational research advances to build upon, with the ultimate goal of 
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1 Group comparisons relevant to AS (Anxiety Sensitivity Index total score; ASI total 
score) could not be conducted.  Participants who were excluded at baseline were not 
asked to complete the ASI, while participants who self-discontinued participation did not 
return their completed questionnaire packets. Complete ASI data therefore was not 
available to conduct meaningful comparisons. 
2 A total of 15 participants (of 90 total participants) pulled their masks during the 
challenge procedure and requested discontinuation of the CO2 administration. No 
significant differences were noted between the Nicotine Deprivation and Non-Nicotine 
Deprivation groups in terms of (1) number of participants who discontinued the challenge 
or (2) the latency to discontinuation (please see Table 1 for details). All participants 
completed the post-challenge questionnaires (SUDS, DSQ, Post-Challenge Avoidance 
Measure) at the point of CO2 discontinuation.  
3 Analyses were conducted with only anticipatory anxiety as a covariate, and patterns of 
main and interactive effects were consistent with those reported here. 
4 Analyses were conducted after all participants with current panic disorder (n = 6; 
Nicotine Deprivation group: n = 2; Non-Nicotine Deprivation group: n = 4) were removed 
from the dataset, and patterns of main and interactive effects were consistent with those 
reported here. 
5 Analyses were conducted, with the same regression models, using nicotine withdrawal 
symptoms (MWS total score, mean centered; continuous variable) rather than 
withdrawal group status (dichotomous variable). Overall patterns of findings were 
consistent with one noted exception: In terms of panic attack symptoms (DSQ total 
score), nicotine withdrawal symptoms were (marginally) significant predictors [t = 1.93, β 
= .22, sr2 = .04, p = .05].   
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6 When post hoc analyses were run with the DSQ subscales, DSQ – Physical Concerns 
(measures panic-relevant physical concerns) and DSQ – Cognitive Concerns (measures 
panic-relevant cognitive concerns), as dependent variables (using the same model), 
identical patterns of findings emerged. The overall models did not contribute any 
significant variance. Gender was the only significant predictor in relation to both DSQ – 
Physical Concerns [β = .25, sr2 = .06, p = .02] and DSQ – Cognitive Concerns [β = .23, 
sr2 = .05, p = .04]. No other significant predictors were noted at the level of main or 
interactive effects.  
Furthermore, the pattern of findings did not change when the DSQ was scored so 
as to index (a) the number of DSM-IV panic attack symptoms (measured continuously; 
each symptom counted if participant rated it at a level of 4 or greater on the 9-point 
Likert-style scale) or (b) the endorsement of DSM-IV panic attacks (yes/no; quantified 
according to DSM-IV criteria with each symptom counted if participant rated it a level of 
4 or greater on the 9-point Likert-style scale) as dependent variables. In terms of the 
number of DSM-IV panic attack symptoms, a hierarchical linear regression was 
conducted and gender emerged as the only significant predictor [β = .29, sr2 = .08, p = 
.009]. With regard to the endorsement of DSM-IV panic attacks (yes/no), a logistic 
regression was conducted and no significant predictors were noted. 
7 In terms of heart rate reactivity, step one of the model accounted for a significant 35.6% 
of variance, [F(5, 69) = 7.61, p < .001]. Only pre-challenge heart rate (recorded at minute 
9 of baseline) was significantly predictive of heart rate reactivity during the challenge (β 
= .58, sr 2 = .29, p < .001). Daily smoking rate was a marginally significant predictor (β = 
-.20, sr 2 = .04, p = .06). No other significant predictors were noted at the level of main or 
interactive effects. Neither steps two [F(2, 67) = .27, p = .76] nor three [F(1, 66) = .16, p 
= .68] accounted for significant portions of variance. 
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 With regard to respiration rate, the overall model, including steps one [F(5, 34) = 
2.05, p = .09], two [F(2, 32) = .06, p = .94], and three [F(1, 31) = .44, p = .51], did not 
account for any significant variance. Only gender (β = .35, sr 2 = .12, p < .05) was 
significantly predictive of respiration rate during the challenge. No other significant 
predictors were noted at the level of main or interactive effects.
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 Male Female Male Female  
Gender3 31 14 24 21 Χ2 = 2.29, p = .19 
Current Psychotropic Medication Use n = 13 n = 18 X2 = 1.07, p = .30 
 M SD M SD  
Age 26.00 9.75 31.73 13.62 * t(88) = -2.29, p < .05 
Education4  2.87 .86 2.87 .86 t(88) = .00, p = 1.0 
Number of Current Axis I Diagnoses .44 .81 .73 1.09 t(88) = -1.42, p = .15 
Negative Affectivity (PANAS) 20.35 8.15 19.27 7.41 t(84) = .64, p = .52 
Daily Smoking Rate, Since Initiation 16.45 9.86 14.91 6.23 t(87) = .88, p = .37 
Daily Smoking Rate, Past Week 15.37 7.00 13.00 5.83 t(88) = 1.75, p = .08 
Age Onset of Daily Smoking 17.20 5.56 17.75 4.86 t(88) = -.50, p = .61 
Number of Daily Smoking Years 9.32 8.35 15.26 13.25 * t(87) = -2.53, p < .05 
FTND – Total5 3.58 1.99 3.23 1.87 t(84) = .83, p = .40 
AUDIT – Total6 10.38 6.35 9.41 7.76 t(83) = .63, p = .52 
Past 30 – Day Marijuana Use7 4.26 3.36 3.81 3.36 t(64) = .54, p = .58 
ASI – Total8 19.13 8.78 17.77 10.04 t(86) = .67, p = .50 
MWS – Total9 5.81 4.32 3.40 4.25 **t(87) = 2.66, p = .009 
Anticipatory Anxiety10 54.09 28.04 50.04 28.22 t(87) = .67, p = .49 
Peri-Challenge Anxiety, Minute 111 60.11 30.91 69.46 24.96 t(83) = -1.53, p = .12 
Peri-Challenge Anxiety, Minute 212 65.12 29.81 70.73 27.85 t(78) = -0.86, p = .38 
Peri-Challenge Anxiety, Minute 313 61.28 32.62 78.90 22.62 **t(78) = -2.81, p = .006 
Post-Challenge Anxiety14 54.65 33.29 64.41 30.20 t(84) = -1.42, p = .15 
Latency to Mask Pulling (minutes)15 1.68 
(n = 7) 
.78 2.02 
(n = 8) 
1.22 t(13) = -.62, p = .54 
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Note. N = 90 (n = 45 per group); * p < .05; ** p < .01; *** p < .001. 1Nicotine Deprivation Group (no smoking for 12 hours prior to 
challenge); 2Non-Nicotine Deprivation Group (smoking as usual and 15 minutes prior to challenge); 3Gender (1 = male; 2 = female); 
4Education Levels: 1 = less than high school; 2 = high school/GED; 3 = some college; 4 = college graduate; 5 = some graduate work; 
6 = graduate degree; 5Fagerstrom Test for Nicotine Dependence – Total score; 6Alcohol Use Disorders Identification Test – Total 
score; 7Frequency of Past 30-Day Marijuana Use, Marijuana Smoking History Questionnaire; 8Anxiety Sensitivity Index – Total score; 
9Minnesota Nicotine Withdrawal Scale – Total score, pre-challenge; 10Pre-Challenge Subjective Units of Distress Scale Ratings 
(SUDS at minute 9 pre-challenge); 11Peri-Challenge Subjective Units of Distress Scale Ratings, Minute 1 (SUDS at minute 1 peri-
challenge); 12Peri-Challenge Subjective Units of Distress Scale Ratings, Minute 2 (SUDS at minute 2 peri-challenge); 13Peri-
Challenge Subjective Units of Distress Scale Ratings, Minute 3 (SUDS at minute 3 peri-challenge); 14Post-Challenge Subjective Units 
of Distress Scale Ratings (SUDS during minute 1 post-challenge); 15Latency to mask pulling and discontinuation of challenge 





































Note. N = 90 (Nicotine Deprivation Group: n = 45; Non-Nicotine Deprivation Group: n = 45); * p < .05, ** p < .01, *** p < .001; 1Levels 
at minute 9 of pre-challenge baseline period; 2Levels immediately post-challenge (minute 1 of recovery period); 3Subjective Units of 
Distress Scale Ratings; 4Nicotine Deprivation Group (no smoking for 12 hours prior to challenge); 5Non-Nicotine Deprivation Group 






















*t(85) = -2.11, p = .03 
t(42) = -.09, p = 0.92 
**t(42) = -2.95, p = .005 
 























***t(86) = -7.83, p < .001 
***t(42) = -6.85, p < .001 













***t(86) = -3.94, p < .001 
**t(42) = -3.38, p = .002 
*t(43) = -2.14, p = .037 









***t(49) = -4.40, p < .001 
***t(25) = -4.24, p < .001 
*t(23) = -2.15, p = .04 
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Variables 1 2 3 4 5 6 7 8 9 10 11 12 M 
(SD) 
Range 
Covariates               
1. Anticipatory Anxiety: 
SUDS1 
- .06   .05 .31**   .19 .25* .23* -.02 .37**  .04  .02  .04 35.94 
(27.8) 
0-100 
2. Anticipatory Anxiety: 
Skin Conductance2 





- - - -.01  .11 -.16  .03  .16 .18 .27** -.13 -.12 38.9% 
female 
- 
4. Number of Axis I  
  Diagnoses 
- - - - .50**  .20 .45**  .15 .32**  .01 -.11 -.10 0.58 
(.97) 
0-3 
5. Negative Affectivity    
  (PANAS)4 
- - - - -  .06 .62** -.07 .07  .00 -.18  .05 19.80 
(7.7) 
10-42 
6. Daily Smoking Rate,        
  Since Initiation 
- - - - - -  .04 -.09 .03 -.19  .12  .01 15.67 
(8.2) 
5-60 
Predictors               
7. Anxiety Sensitivity            
  (ASI – Total)5 
- - - - - - - -.07 .12  .13  -.06  .09 18.44 
(9.4) 
2-48 
8. Group Status6 
 
- - - - - - - - .15  .05  .06  .05 50% 
each 
- 
Dependent Variables               
9. Post-Challenge     
  Anxiety: SUDS7  
- - - - - - - - - .43**  .08 -.20 59.53 
(31.9) 
0-100 
10. DSQ – Total8 - - - - - - - - - -  .09 -.34** 52.19 
(28.2) 
6-126 
11. Skin Conductance  
  Reactivity-Composite9 
- - - - - - - - - - -  .07 3.46 
(2.8) 
1-15.67 
12. Post-Challenge  
    Avoidance10 





Note. N = 90 (Nicotine Deprivation Group: n = 45; Non-Nicotine Deprivation Group: n = 45); *p < .05, **p < .01. 1Anticipatory Anxiety: 
Subjective Units of Distress Scale Ratings (minute 9 of pre-challenge baseline); 2Anticipatory Anxiety: Skin Conductance (minute 9 of 
pre-challenge baseline); 3Gender (1 = male; 2 = female); 4Positive Affect Negative Affect Scale – Negative Affect subscale; 5Anxiety 
Sensitivity Index – Total score; 6Group Status (1 = Nicotine Deprivation Group; 2 = Non-Nicotine Deprivation Group); 7Post-Challenge 
Anxiety: Subjective Units of Distress Scale Ratings (first minute post-challenge); 8Diagnostic Sensations Questionnaire – Total score; 
9Skin Conductance Reactivity - Composite (minutes 1-4 of challenge); 10Post-Challenge Avoidance Measure – Total Rating of 







Table 4. Hierarchical Linear Regressions: Main and Interactive Effects 
     ∆R2           t                    β          sr2                 p   
                       (each predictor)  
Dependent Variable: Post-Challenge SUDS Anxiety Ratings1  
Step 1     .17      .010 
Pre-Challenge SUDS Ratings5  2.05  .23 .05  .043 
Gender6     1.51  .16 .02  .135 
Number of Axis I Diagnoses  2.32  .30 .06  .023 
Negative Affectivity (PANAS)            -1.03            -.13 .01  .305 
Daily Smoking Rate, Since Initiation  -.36            -.04 .00  .714 
Step 2     .00      .904 
 ASI – Total7     -.14            -.02 .00  .888 
Group Status8         .42  .04 .00  .673  
Step 3     .01      .349 
ASI x Group     -.94            -.34 .01  .349 
Dependent Variable: DSQ – Total Score2 
Step 1     .11      .091 
Pre-Challenge SUDS Ratings   -.01            -.00 .00  .985 
Gender     2.43  .26 .07  .017 
Number of Axis I Diagnoses         .83  .11 .00  .409 
Negative Affectivity (PANAS)              -.76           -.10 .00  .449 
Daily Smoking Rate, Since Initiation       -1.48           -.17 .02  .143  
Step 2     .02      .316 
 ASI – Total    1.52  .21 .02  .131 
Group Status               -.07            -.00 .00  .945  
Step 3     .00      .630 
ASI x Group     -.48            -.18 .00  .630  
Dependent Variable: Skin Conductance Reactivity (Composite)3 
Step 1     .73              < .001 
Pre-Challenge SC9            12.97  .84 .70          < .001 
Gender     1.02  .06 .01  .311 
Number of Axis I Diagnoses   -.51            -.04 .00  .607 
Negative Affectivity (PANAS)   -.74            -.05 .00  .460 
Daily Smoking Rate, Since Initiation   .56             .03 .00  .571 
Step 2     .00      .803  
 ASI – Total       .45  .03 .00  .654  
Group Status         -.43            -.03 .00  .662 
Step 3     .00      .662 
ASI x Group        .44   .09 .00  .662 
Dependent Variable: Level of Avoidance of a Future Challenge4 
Step 1     .10      .123 
Pre-Challenge SUDS Ratings     .83             .09 .00  .409  
Gender     -1.43            -.16 .02  .154 
Number of Axis I Diagnoses  -2.66            -.37 .08  .009 
Negative Affectivity (PANAS)    2.01             .27 .05  .048 
Daily Smoking Rate, Since Initiation     .28             .03 .00  .776 
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Step 2     .01      .490 
 ASI – Total        .56             .08 .00  .572 
Group Status         1.08             .12 .01  .280 
Step 3     .00      .397 
ASI x Group        -.85            -.32 .01  .397 
 
 
Note. N = 90; 1Post-Challenge Subjective Units of Distress Scale Ratings (first minute 
post-challenge); 2Diagnostic Sensations Questionnaire – Total score (completed 
immediately post-challenge); 3Skin Conductance Reactivity – Composite (minutes 1-4 of 
challenge); 4Post-Challenge Avoidance Measure; 5Pre-Challenge Subjective Units of 
Distress Scale Ratings (minute 9 of pre-challenge baseline); 6Gender (1 = Male; 2 = 
Female); 7Anxiety Sensitivity Index – Total score (mean-centered); 8Group status (1 = 
Nicotine Deprivation; 2 = Non-Nicotine Deprivation); 9Pre-Challenge Skin Conductance 



















Table 5. Post Hoc Tests: ANOVA Results, Between-Subjects Effects 
         F  η2             p 
Repeated Measures ANOVA 
Dependent Variable: Peri-Challenge Anxiety, Minutes 1-31  
Covariates 
Pre-Challenge SUDS Ratings5  4.46  .06  .038 
Gender6       .99  .01  .321 
Number of Axis I Diagnoses  3.11  .04  .082 
Negative Affectivity (PANAS)             2.57  .03  .113  
Daily Smoking Rate, Since Initiation 2.23  .03  .139 
Main Effects      
  ASI – Total7     4.69  .06  .034  
Group Status8     1.81  .02  .182 
Interactive Effect 
ASI x Group     5.53  .07  .022 
Univariate ANOVA 
Dependent Variable: Challenge Anxiety – Minute 12 
Covariates 
Pre-Challenge SUDS Ratings  8.08  .10  .006 
Gender     1.74  .02  .191 
Number of Axis I Diagnoses  2.02  .02  .160 
Negative Affectivity (PANAS)               .57  .00  .449 
Daily Smoking Rate, Since Initiation 4.03  .05  .048 
Main Effects      
 ASI – Total     5.20  .06  .026 
Group Status        1.91  .02  .171  
Interactive Effect  
ASI x Group    5.70  .07  .020  
Dependent Variable: Challenge Anxiety – Minute 23 
Covariates 
Pre-Challenge SUDS Ratings  2.74  .04  .103 
Gender     1.11  .01  .295 
Number of Axis I Diagnoses  2.90  .04  .093 
Negative Affectivity (PANAS)               .89  .01  .347 
Daily Smoking Rate, Since Initiation   .50  .00  .480 
Main Effects      
 ASI – Total    1.79  .02  .184 
Group Status         .22  .00  .639  
Interactive Effect 
ASI x Group    8.92  .11  .004 
Dependent Variable: Challenge Anxiety – Minute 34 
Covariates 
Pre-Challenge SUDS Ratings  1.50  .02  .224 
Gender       .26  .00  .610 
Number of Axis I Diagnoses  2.08  .03  .153 
Negative Affectivity (PANAS)             5.07  .07  .028 




Main Effects      
 ASI – Total    4.90  .06  .030 
Group Status       3.53  .05  .060   
Interactive Effect 
ASI x Group    1.34  .02  .251 
 
 
Note. N = 90; 1Subjective Units of Distress Scale (SUDS) Anxiety Ratings, Challenge 
Minutes 1-3; 2Subjective Units of Distress Scale (SUDS) Anxiety Ratings, Challenge 
Minute 1; 3Subjective Units of Distress Scale (SUDS) Anxiety Ratings, Challenge Minute 
2; 4Subjective Units of Distress Scale (SUDS) Anxiety Ratings, Challenge Minute 3; ; 
5Pre-Challenge Subjective Units of Distress Scale Ratings (minute 9 of pre-challenge 
baseline); 6Gender (1 = Male; 2 = Female); 7Anxiety Sensitivity Index – Total score 

































Figure 1: Conceptual model: AS as moderator of the association between nicotine 
































































Nicotine deprivation – CO2:  
(45 participants): to refrain from 




Non-nicotine deprivation – CO2:  
(45 participants): to smoke as usual 
between sessions 
Baseline Assessment:  
Part I:   informed consent, diagnostic interview,   
validated medical screening interview, and 
questionnaire completion 
Part II:  CO analysis of breath samples 
Part III: stratified random assignment of participants to                  
             one of two experimental conditions   
Part IV:  $10 compensation       
 
     
              (groups matched for gender) 








radio announcements, and 
flyers posted in local 
businesses and on 
community bulletin boards 
 
Second Session  
(CO2 Administration): 
Part I:  complete CO breath analyses 
note: subjects found to have not refrained 
were discontinued at this point and not 
compensated for the second session 
Part II: undergo laboratory procedure 
Part III:  complete challenge assessment          
battery 
Part IV:  debriefing  




(CO2 Administration):  
Part I:   smoke 1 cigarette 15 minutes 
             prior to challenge 
Part II:  complete CO breath analyses 
Part III: undergo laboratory procedure 
Part IV: complete challenge assessment  
battery 
Part V:   debriefing 


























Figure 5: Nicotine withdrawal symptoms over time by withdrawal group 
 
